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formed hemostatic clots. Two potential approaches were pursued: 1) PA-loaded platelets that release the
thrombolytic from its granular stores upon activation, and 2) a thrombolytic chimeric protein that specifically
binds to human platelets and activated when the platelets are incorporated into a growing thrombus. In our
first approach, we desired to develop a strategy for producing platelets ex-vivo from cultured megakaryocytes
that ectopically expressed urokinase-PA (uPA). No group had successfully produced sufficient ex-vivo
generated platelets before, to side step this issue we infused ex-vivo generated megakaryocytes and showed
that we can achieve a significant number of donor-derived platelets from these infused megakaryocytes in a
murine model. The resulting platelets were normal in size, surface markers, circulating half-life, and were
functional. Infused megakaryocytes localized to the pulmonary vasculature to shed platelets. We
demonstrated, beginning with megakaryocytes derived from a transgenic mouse that ectopically express and
store uPA in their alpha-granules that we can interfere with thrombosis by platelets generated from these
megakaryocytes. In the second approach we produced a chimeric protein by fusing a single chain variable
fragment (scFv) directed to the human-αIIb (hαIIb) platelet receptor subunit, with a human thrombin
activatable pro-urokinase (uPA-T). The fusion protein (anti-PLT scFv/uPA-T) bound specifically to human
and to transgenic mice platelets that expressed hαIIb, termed hαIIb+ mice, but did not bind to wildtype (WT)
mouse platelets. Anti-PLT scFv/uPA-T retained its zymogenic properties until activated by thrombin. HαIIb+
mice were protected from forming occlusive thrombi for at least 10 hrs post anti-PLT/uPA-T treatment in
contrast to the short functional half-life of soluble uPA-T. Thus this dissertation presents two distinct
strategies that in proof of principle studies are each promising as approaches for effective and targeted platelet
directed thrombolytic, which merit further study to test clinical applicability.
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ABSTRACT 
 
DEVELOPING NOVEL PLATELET-BASED TARGETING STRATEGIES FOR 
THROMBOLYTICS 
Rudy E. Fuentes 
Mortimer Poncz 
 
Use of plasminogen activators (PAs) as thrombolytic drugs is restricted to life 
threatening thrombotic settings because these therapies are associated with a high risk of 
bleeding. We hypothesize that platelet-delivered PAs would preferentially lyse nascent, 
pathological clots that are actively recruiting platelets, while sparing pre-formed 
hemostatic clots.  Two potential approaches were pursued: 1) PA-loaded platelets that 
release the thrombolytic from its granular stores upon activation, and 2) a thrombolytic 
chimeric protein that specifically binds to human platelets and activated when the 
platelets are incorporated into a growing thrombus. In our first approach, we desired to 
develop a strategy for producing platelets ex-vivo from cultured megakaryocytes that 
ectopically expressed urokinase-PA (uPA). No group had successfully produced sufficient 
ex-vivo generated platelets before, to side step this issue we infused ex-vivo generated 
megakaryocytes and showed that we can achieve a significant number of donor-derived 
platelets from these infused megakaryocytes in a murine model. The resulting platelets 
were normal in size, surface markers, circulating half-life, and were functional. Infused 
megakaryocytes localized to the pulmonary vasculature to shed platelets. We 
demonstrated, beginning with megakaryocytes derived from a transgenic mouse that 
ectopically express and store uPA in their alpha-granules that we can interfere with 
thrombosis by platelets generated from these megakaryocytes.  In the second approach 
 
vi 
we produced a chimeric protein by fusing a single chain variable fragment (scFv) 
directed to the human-αIIb (hαIIb) platelet receptor subunit, with a human thrombin 
activatable pro-urokinase (uPA-T). The fusion protein (anti-PLT scFv/uPA-T) bound 
specifically to human and to transgenic mice platelets that expressed hαIIb, termed 
hαIIb+ mice, but did not bind to wildtype (WT) mouse platelets. Anti-PLT scFv/uPA-T 
retained its zymogenic properties until activated by thrombin. HαIIb+ mice were 
protected from forming occlusive thrombi for at least 10 hrs post anti-PLT/uPA-T 
treatment in contrast to the short functional half-life of soluble uPA-T. Thus this 
dissertation presents two distinct strategies that in proof of principle studies are each 
promising as approaches for effective and targeted platelet directed thrombolytic, which 
merit further study to test clinical applicability. 
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Chapter 1 
Introduction 
 
 
1.1 Background 
 
1.1.1 Pathogenesis of thrombosis 
Thrombosis can occur in either the arterial or venous systems and both can be life 
threatening. Acute arterial thrombosis is the proximal cause of most cases of myocardial 
infarction (heart attack) and of about 80% of strokes, collectively the most common 
cause of death in the developed world, and venous thromboembolism is the third leading 
cause of cardiovascular associated death (1). Thrombosis manifests itself due to an 
imbalance in hemostatic procoagulant and anticoagulant mechanisms that maintain 
normal physiological conditions. The endothelium is a major contributor to maintaining 
this balance by providing an antithrombotic surface that inhibits platelet adhesion and 
clotting. However, when the endothelium is perturbed by physical forces or by 
inflammation, the cells undergo programmatic biochemical changes that culminate in 
their transformation to a prothrombotic surface (2). During vascular injury, the 
coagulation system is activated with the conversion of thrombin from prothrombin by 
exposure of tissue factor. Thrombin is able to cleave fibrinogen to form fibrin, which 
contributes to the stabilization of the platelet plug. Almost concurrently, fibrinolysis goes 
into effect to limit and eventually remove the thrombus and recanalized the vessel. It is 
important to note that coagulation and fibrinolysis are two antagonistic phenomena and 
a balance is required amongst their respective activators and inhibitors for the 
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processes to be physiologic (3). These mechanisms involved in keeping the hemostatic 
balance will be discussed in more detail in the sections that follow. 
 
1.1.2 History of platelet biology 
The discovery of platelets is best attributed to a summation of work by different 
scientists dating back to 1842, when platelets were recognized as little globules 
morphologically different then red or white blood cells (4). The most powerful evidence 
was provided by Giulio Bizzozero in 1881 and 1882, using intravital microscopy, he 
described platelets anatomically as well as their adhesive properties upon damage to the 
vascular wall (5, 6). Interestingly, 12 years before his platelet publication, Bizzozero 
observed large irregular cells in the bone marrow with highly lobulated, multilobed 
nuclei, but their significance was unknown until William Howell with his camera lucida 
studies in 1890 was able to corroborate on those observations and coined the term 
megakaryocytes (7). In 1906, Wright suggested that blood platelets were derived from 
the cytoplasm of megakaryocytes noting the similarities in both cells when exposed to a 
new polychrome staining solution (Wright’s stain) (8), and with these studies the basic 
elements of thrombopoiesis were established.  
 
1.1.3 Megakaryocyte development  
During megakaryopoiesis, committed hematopoietic stem cells (HSCs) undergo several 
stages of differentiation resulting in mature megakaryocytes that produce and release 
platelets into the circulation (9). HSCs are found primarily in the bone marrow (10, 11), 
and during mammalian development, they can also be found in the embryonic yolk sac, 
fetal liver, and spleen (12). To study megakaryocytic progenitors, in-vitro clonal assays 
were developed to analyze the cellular basis of lineage commitment and cell 
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differentiation (13, 14). Based on these studies, a few megakaryocytes have been shown 
to arise in culture (Figure 1-1) from mixed lineage primitive cells that are termed colony-
forming unit-granulocyte-erythroid-monocyte-megakaryocyte (CFU-GEMM) (15). More 
differentiated burst-forming unit-megakaryocytes (BFU-Meg) are able to produce larger 
complex colonies that include satellite collections of megakaryocytes. The colony-
forming unit-megakaryocyte (CFU-Meg) can form 3-50 mature megakaryocytes and are 
the first fully committed cells to the megakaryocyte lineage base on their unique cell 
surface markers (CD41+FcγlowCD34+CD38+CD9-) (16). Subsequent cells are 
morphologically closer to actual megakaryocytes then their earlier counterparts. The first 
of these immediate megakaryocyte precursors is the promegakaryoblast, also known as a 
stage I megakaryocyte. It is not able to produce colonies in-vitro, but able to mature into 
a single megakaryocyte in culture (17). The megakaryoblast has a diploid nucleus and a 
diameter of 10-50 µm, and the promegakaryocyte or stage II megakaryocyte is 20-80 µm 
in diameter with developing granules in its cytoplasm (18).  
Once the megakaryocyte precursors reach maturity, they have undergone a series 
of modifications including cytoplasm maturity, which involves the development of 
platelet specific proteins, organelles, and membrane systems that will also be present in 
platelets. They also undergo endomitosis, a process unique to megakaryocytes in 
mammals when they become polyploid by repeated cycles of DNA replication without 
undergoing cytokinesis (19). The final mature megakaryocyte is 50-100 µm diameter and 
contains a single large polyploidy nucleus (2-256N) (20). 
Regulation of megakaryopoiesis has been studied in detail, and it has been shown that 
several cytokines are influential in maturation and development of megakaryocyte 
precursors. The most influential is thrombopoietin (TPO), a potent growth factor that is 
heavily involved in maturation and growth of early hematopoietic cells and the 
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megakaryocyte lineage (21). Stem cell factor (SCF), also known as kit ligand, has been 
shown to be influential during the early stages of megakaryopoiesis (22, 23). Interleukin 
6 (IL-6) and 11 are also involved in regulation and seem to work synergistically with TPO 
and IL-3 (24-26). 
 
1.1.4 Platelet development 
Platelets are the final product of megakaryopoiesis and are essentially cytoplasmic 
portions of matured megakaryocytes. In humans, platelets have a circulating half-life of 
7-10 days, (27) and are produced at a steady rate of 1011 daily with an increase of more 
then 20-fold in times of heightened demand (15). It is estimated that one human 
megakaryocyte can produce ~103 platelets and ~102 in mice (28).  
The mechanism by which megakaryocytes release platelets in circulation is still 
poorly understood in part because of the rarity (<0.1%) of megakaryocyte in normal bone 
marrow. Older studies attempted to explain the mechanism by proposing models that 
focused on platelet budding from the surface of megakaryocytes and cytoplasmic 
fragmentation via the demarcation membrane system (29-31). Both of these models have 
lost support due to inconsistent observations, and primarily because of the discovery of 
TPO, which facilitated ex-vivo culture systems for the study of platelet biogenesis. 
Currently the proplatelet formation model is more acceptable and is closely related to 
Wright’s observation in 1906, that platelets were produced from long pseudopod 
extensions of megakaryocytes that then release platelets (32). 
Current ex-vivo studies have supported that platelets are made from nodes at the 
tips of proplatelet strands (33), but these simplistic systems lack the three dimensional 
organization, supportive cells and flow characteristics seen within the marrow. Direct 
visualization of live calvaria marrow using multiphoton intravital microscopy suggest 
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that 
 
 
Figure 1-1. Megakaryopoiesis and platelet development. HSCs undergo several 
stages of differentiation until they commit to a myeloid progenitor cell. The CFU-GEMM 
is of mixed lineage capable of producing mixed blood cells. The BFU-Meg is also able to 
produce a mixture of cells as well as large megakaryocyte colonies. The CFU-Meg are the 
first fully committed cells to the megakaryocyte lineage. Promegakaryoblast are 
considered a stage I megakaryocyte followed by megakaryoblast which has a developed 
nucleus and the promegakaryocyte are stage II megakaryocyte with developing granules 
in its cytoplasm. Shown are some of the cytokines involved at different stages of 
megakaryopoiesis.  
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 that megakaryocytes release into the bloodstream large cytoplasmic fragments, not 
small pseudoplatelets, that must be re-organized into mature platelets within the 
organism (34). Indeed, older studies based on morphologic analysis of the lungs and 
quantification of megakaryocyte like polyploid nuclei in the pulmonary venous system 
suggest that whole megakaryocytes travel to the lungs where they release their platelets 
(35-39). These potential mechanisms involving platelet formation from megakaryocytes 
by cytoplasmic shedding at the bone marrow or pulmonary vasculature beds may explain 
why it has been challenging to produce large numbers of platelets from megakaryocytes 
ex-vivo. 
 
1.1.5 Platelet role in thrombus formation 
Hemostasis is the process by which the body maintains the fluidity of blood under 
physiological conditions and prevents excessive blood loss after injury (40). Platelets are 
essential in hemostasis by forming a monolayer that supports thrombin generation and 
platelet aggregation, contributing to stable thrombus formation. The degree of 
involvement by platelets in a growing clot depends on the kind of circulation, for 
example arterial thrombi form under conditions of high flow are composed mainly of 
platelet aggregates bound together by thin fibrin strands. In contrast, venous thrombi 
form in areas of stasis and are predominantly composed of red cells, with a large amount 
of interspersed fibrin and relatively few platelets (41). 
Under high shear arterial circulation, endothelial derived inhibitory factors 
suppress platelet activation, including prostaglandin I2 (PGI2), and nitric oxide (NO) as 
well as expression of CD39 on endothelial cells (Figure 1-2) (42-44). After vascular injury 
and exposure of subendothelium, a multistep complex process goes into effect, which 
involves a diverse array of extracellular matrix components that interact with platelets to 
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form a platelet plug. The platelet plug formation can be divided into three stages (45), 
starting with the “initiation” step (Figure 1-2), when platelets roll on activated 
endothelial cells, a process mediated by P-selectin and E-selectin (46, 47). The platelets 
are able to bind to von Willebrand factor (VWF) via its GPIb/IX/V membrane receptor, 
establishing a transient bond that slows them down and facilitate their activation (48). 
The platelets also adhere to exposed collagen either directly via the Glycoprotein (GP) VI 
and α2β1 integrin (49). This interaction promotes platelet activation, which leads to 
morphological changes, including release of granular content and expression of activated 
GPIIb/IIIa, the major platelet integrin that mediates platelet aggregation. 
During the “extension” stage (Figure 1-2), additional platelets are recruited when 
activated platelets release agonists, such as adenosine diphosphate (ADP) and 
thromboxane A2 (TxA2), which leads to further activation of adherent platelets. In 
addition tissue factor expressed at low levels by cytokine stimulated endothelial cells 
promotes local generation of thrombin (50). Thrombin is able to activate platelets 
through cleavage of the platelet G-protein linked protease activated receptors (PAR-1) 
(51) as well as cleavage of GPV of the GPIb-IX-V complex, which allows thrombin to bind 
to GPIbα (52). Other surface molecules may also play an accessory role in platelet 
activation by thrombin. 
The last stage of the platelet plug formation stabilizes the plug to prevent 
premature disaggregation. The stabilization is attributed to the close contact between 
activated platelets that allows contact dependent signaling (53). The final process of 
stabilizing the platelet plug involves the coagulation cascade, which is able to transform 
soluble fibrinogen into insoluble fibrin by thrombin, thus forming the fibrinous 
meshwork. 
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Figure 1-2. Platelet plug formation under arterial circulation. Platelet adhesion 
is started when VWF links collagen to platelets at sites of injury. The activated platelets 
release ADP, thromboxane and other chemicals that activate more platelets. Platelet 
adhesion occurs via the collagen receptors and the GPIb/IX/V complex followed by 
aggregation of additional platelets through GPIIb/IIIa, which forms a bridge through 
fibrinogen to other activated platelets. 
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1.1.6 Fibrinolysis 
The fibrinolytic pathway has diverse roles including regulation of cellular activity and 
tissue development, but its primary functions is the conversion of inactive proenzymes to 
active forms for fibrin degradation and thus maintains blood fluidity by breaking down 
blood clots (54). The central protein in this process is plasminogen, which is converted 
by PAs into plasmin that lyse the clot. The vascular endothelium is able to release uPA 
and tissue plasminogen activator (tPA) the two PAs involved in the thrombolytic process. 
PAs work to activate plasminogen to plasmin (Figure 1-3), which is able to lyse fibrin by 
attacking it at several sites in the molecule, leading to fibrin clot lysis. The mechanism of 
activation by both PAs is by binding to specific cellular receptors, uPA binds to a 
glycolipid anchor membrane protein uPAR, and tPA to a type-II transmembrane protein 
(55).  
Plasmin’s activity is controlled by an antiplasmin inhibitor, α2-antiplasmin, while 
tPA and uPA are regulated by forming complexes with plasminogen activator inhibitor-1 
(PAI-1), which is found in both plasma and platelet a-granules (56). Over 90% of PAI-1 is 
present in the a-granules in an inactive form, which is thought to be one of the reasons 
why platelet-rich thrombi are resistant to thrombolytic therapy (57, 58). 
 
1.1.7 Key mediators of fibrinolysis 
Plasminogen is synthesized primarily in the liver and is found in high concentration in 
plasma (59). Plasminogen is a 92-kDa single-chain glycoprotein consisting of 791 amino 
acid (aa) residues with Glu as the N-terminal amino acid. The structure is made up of 
five homologous kringle-like domains that mediate the interactions of the zymogen to 
regulatory sites, and cell surface receptors. Cleavage by PAs between Arg561-Val562 
converts plasminogen to the plasmin resulting in a heavy chain (A chain) and a 
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Figure 1-3. Fibrinolytic cascade. Schematic cartoon of the fibrinolytic cascade. 
Shown in the center is a fibrin clot at a site of vascular injury. Also shown is activation of 
plasminogen by PAs to produce plasmin, which is able to degrade the fibrin clot.  
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light chain (B chain) that is enzymatically active (60). 
Endothelial cells synthesize and secrete tPA as a single chain active enzyme that 
circulates in plasma at relative low concentrations with a half-life of 5 to 7 min (61). It is 
made up of 527 aa with a molecular weight (MW) of 70 kDa. tPA is composed of five 
domains; 1) the N-terminal region of 47-residues (4-50 aa) make the finger like domain 
homologous with fibronectin; 2) aa 50-87 are homologous with the epidermal growth 
factor (GFD); 3) two kringle regions (aa 87-176 and 176-262) which are homologous with 
the five kringles of plasminogen; and 4) a serine proteinase domain (aa 276-527) with 
the catalytic site His322, Asp371, and Ser478 (62). The high affinity binding of tPA to fibrin 
is mediated by both the finger and kringle two domains. This is important because tPA is 
a poor enzyme in the absence of fibrin, but in the presence of fibrin, enhances the 
activation rate of plasminogen (63).  
uPA was first isolated from urine, hence the name urokinase. uPA is synthesized 
by vascular endothelial and smooth muscle cells, by epithelial cells, fibroblasts, 
monocytes/macrophages, and also by multiple malignant tumors (64-66). Unlike tPA 
that is mainly involved in fibrinolysis, uPA has additional functions in cell migration and 
tissue remodeling (67). uPA is secreted as a single chain polypeptide (scuPA) with a 
molecular weight of 54 kDa that consists of 411 amino acid residues (68). The structure 
of uPA (Figure 1-4) is subdivided into three domains, starting with the N-terminal 
domain homologous to the epidermal GFD (aa 9-45) responsible for the interaction of 
urokinase with the uPAR/CD87 receptor. The kringle domain (aa 46-143) contains a 
sequence that interacts with the specific inhibitor PAI-1. The C-terminal catalytic 
domain, (aa 144-411) includes the active site made up of serine proteases amino acid 
triad His204, Asp255, and Ser356 (69, 70). Each domain of the protein has a rigid 
structure supported by internal disulfide bonds, while intramolecular disulfide bonds 
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maintain the orientation of amino acid residues in the active center of the proteolytic 
domain. This has been confirmed by loss of enzymatic activity after destruction or 
irregular formation of disulfide bonds (71). The form in which single-chain uPA (scuPA) 
is secreted has low intrinsic activity but can be cleaved at several sites to make it active. 
Matrix metalloproteinase (Figure 1-4) (MMP-3) specifically hydrolyzes the 
Glu143−Leu144 peptide bond of scuPA and in its two-chain (tcuPA) derivative, yielding a 
17-kDa NH2-terminal domain comprising uPAR’s binding site and a 32-kDa COOH-
terminal moiety containing the serine proteinase domain of uPA (72). Plasmin cleaves 
the Lys158-Ile159 peptide bond producing fully active uPA as tcuPA, connected by 
disulfide bonds. The rate of plasminogen cleavage by tcuPA is more then 200-fold higher 
then the rate of cleavage by scuPA (73). This form of uPA lack the GFP domain so it is 
not able to bind to its receptor uPAR, which makes it ideal for therapeutic studies since it 
eliminates any side effects that result from receptor activation such as inflammation. 
 
1.1.8 Clinical use of PAs and their limitations 
One major form of treatment of occlusive thrombosis consists of pharmacological 
dissolution of the blood clot by intravenous infusion of PAs that activate the fibrinolytic 
system (74). Physical disruption of plaques (atherectomy) is also used as treatment 
especially in peripheral arterial disease of the lower extremities (75). There are several 
thrombolytic drugs in clinical use, including uPA and streptokinase that are effective 
thrombolytics, but are not fibrin specific. Additionally, they also decrease circulating and 
intra-thrombus plasminogen, potentially leading to reduction in clot lysis (76). 
Furthermore, the bacterial derived streptokinase is immunogenic, resulting in drug 
resistance, fevers, and allergic reactions (77). Second generation agents such as tPA and 
scuPA are more fibrin selective and decrease the depletion of circulating plasminogen 
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Figure 1-4. Structure of scuPA and its various cleaved forms. scuPA structure is 
composed of three domains, the N-terminal domain contains the GFD, responsible for 
the interaction of uPA with uPAR. The kringle domain contains a sequence that interacts 
with the specific inhibitor PAI-1. The C-terminal contains the catalytic domain with the 
serine proteases active site. scuPA can be cleaved by different components to form the 
active for tcuPA. Matrix metalloproteinase cleaves between Glu143−Leu144 and plasmin 
can cleave between Lys158-Ile159 resulting in the two-chain derivatives.  
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and fibrinogen (78). All of these agents induce thrombolysis, and while there are 
differences in fibrin binding affinity and other properties, in essence turn out to have 
similar clinical efficacy and such side effects as the consumption of circulating fibrinogen 
and plasminogen and the development of bleeding complications (79). These agents also 
have short half-lives and require intravenous (IV) administration. Local infusions of 
these PAs at the site of pathologic thrombus have limited improved efficacy (80-82). 
 
1.2 Dissertation objective 
 
Cardiovascular disease is estimated to be responsible for 17 million deaths per year, 
making it one of the largest cause of mortality worldwide (83). Current anti-thrombotic 
therapies reduce the risk of recurrent cardiovascular events, but increase the risk of 
bleeding in part because they act systemically.  
An improved thrombolytic agent would have better targeting of activity to sites of 
developing clots. For thromboprophylaxis use, an ideal agent needs to avoid targeting a 
mature thrombus and only lyse growing thrombi. An additional useful feature would be 
to have a therapeutic agent with a prolonged lifespan, preventing the development of 
untoward thrombi over several days and allowing injured vessels to heal without 
developing recurrent, pathologic thrombi. As proof of principle, our group has shown 
that uPA ectopically expressed in platelets using a transgenic approach is highly effective 
in preventing arterial and venous thrombosis and that transfusion of 5% of the platelet 
mass protects WT mice from clotting without causing systemic fibrinolysis or 
spontaneous bleeding (84). Based on these preliminary data, we envision achieving high 
levels of megakaryocyte-specific expression of uPA in human megakaryocytes derived 
from in- vitro differentiation of embryonic stem cells, allowing one to produce 
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modified uPA-containing platelets for targeting to sites of injury (Figure 1-5). To reach 
that stage, we first need to develop strategies that facilitate the production of such donor-
derived platelets. One way to accomplish this is by infusing ex-vivo derived mature 
megakaryocytes as a source for donor-derived platelets.  
Another platelet-centric strategy for producing effective thromboprophylaxis is 
by developing a recombinant modular PA that specifically binds to the platelet surface 
and that is activated only at a site of active clotting (Figure 1-5). A recent study targeting 
red blood cells confirmed the targeting efficiency, safety and efficacy for pulmonary 
thromboprophylaxis using a mutated low molecular weight scuPA, which is specifically 
activated by thrombin (85). Using the same thrombin-activatable pro-enzyme fused to 
an anti-platelet specific scFv antibody fragment would likely prolong the half-life of the 
mutated uPA and provide a better targeting mechanism to sites of growing thrombi.  The 
thrombin generated from the growing thrombi serves as a control mechanism that 
activates the uPA-T, which can conceivably limit adverse effects, and increase its 
duration in blood, prolonging its intravascular effect, and thus permitting use as 
prophylaxis. 
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(B) 
(A) 
 
 
 
Figure 1-5. Depiction of the two strategies proposed. The two approaches 
proposed are shown starting with (A) the expression of uPA at high levels in developing 
megakaryocytes and produce platelets that will stored the zymogen in their alpha 
granules to be release in a targeted fashion at sites of injury. The second approach (B) 
deals with producing a chimeric protein that will bind directly to the surface of platelets 
via the aIIb receptor and will deliver a thrombin activatable lmw-uPA to the thrombus 
sites, leading to clot lysis via fibrinolysis. 
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Chapter 2 
Infusing mature megakaryocytes into mice yields 
functional platelets 
 
 
2.1 Abstract 
 
Thrombopoiesis, the process by which circulating platelets arise from megakaryocytes, 
remains incompletely understood. Prior studies suggest that megakaryocytes shed 
platelets in the pulmonary vasculature (35, 36, 38, 39, 86). To better understand 
thrombopoiesis and to develop a potential platelet transfusion strategy that is not 
dependent upon donors, we examined whether megakaryocytes infused into mice shed a 
significant number of platelets. We found that infused megakaryocytes led to clinically 
relevant increases in platelet numbers. The released platelets were normal in size, 
displayed appropriate surface markers, and had a near normal circulating half-life. The 
functionality of the donor-derived platelets was also demonstrated in-vivo. The infused 
megakaryocytes mostly localized to the pulmonary vasculature, where they appeared to 
shed platelets. These data suggest that it may be unnecessary to generate platelets from 
ex-vivo grown megakaryocytes to achieve clinically relevant increases in platelet 
numbers. 
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2.2 Background 
 
In 2001, platelet transfusions in the USA totaled 10,196,000 units, an increase of 12.6% 
from 1999 (87). While the need for healthy platelet donors is increasing, there is a 
significant donor shortage due to the growing population of patients with serious 
medical illnesses associated with thrombocytopenia and hemorrhages. Platelets for 
transfusions also suffer from the following concerns: variability of donor units in terms 
of number of platelets and functionality, risk of donor-to-patient infectious transmission, 
the short lifespan of room temperature stored platelets (necessary to maintain platelets 
of normal life-span), bacterial contamination during this storage, and the development 
of platelet alloantibodies in multiply transfused patients. All of these problems highlight 
a need for new strategies to generate platelets for infusion therapy.  
Two models of thrombopoiesis have been proposed: The release of platelets 
produced from megakaryocytes within the marrow space and the release of platelets by 
circulating megakaryocytes within the pulmonary vasculature (39). In-vitro studies 
suggested that platelets form nodes at the tips of proplatelets strands (33). However, 
direct visualization of live calvaria marrow using multiphoton intravital microscopy 
suggested that megakaryocytes, adjacent to the vascular space, release large cytoplasmic 
fragments into the bloodstream (34). These must then be re-organized into mature 
platelets. Older studies based on morphologic analysis of the lungs and quantification of 
megakaryocyte-like polyploid nuclei in the pulmonary venous system suggested that 
megakaryocytes travel to the lungs where they release their platelets (35, 36, 38, 39, 86). 
Final platelet formation from megakaryocyte cytoplasmic shedding at the 
marrow/endothelial interface or in the pulmonary vasculature beds may explain 
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why it has been challenging to produce large numbers of platelets from megakaryocytes 
grown in-vitro without simulating special niches and/or flow conditions.  
Derivation of platelets from megakaryocytes in culture was first reported in 1995 
(88), but has been difficult to quantitatively upscale. To date the best-published result 
from infused in-vitro produced platelets used irradiated mice with low platelet counts 
(~104/µl) (10). Even in this setting, peak donor platelet counts were 1%-2% of this low 
number of platelets and this miniscule increase is unlikely to be of clinical utility. Given 
the limited success with which platelets have been generated ex- vivo, we examined 
whether infused megakaryocytes release platelets in-vivo. We found that by infusing ex-
vivo generated megakaryocytes into mice, we can achieve approximately an 100-fold 
increase in recipient platelet count over the prior best published results, thereby 
reaching clinically relevant levels of donor platelet. These platelets have a slightly shorter 
half-life than infused platelets, but are normal in size and surface markers and are 
functional in two clotting models. We also show that the infused megakaryocytes appear 
to be trapped in the pulmonary bed where they shed their cytoplasm.  
 
 
2.3 Material and methods 
 
2.3.1 Characterization of the mice studied  
Donor cells and platelets were derived from C57BL/6 WT mice (Jackson Laboratory) or 
mUK transgenic mice that ectopically expressed murine urokinase within 
megakaryocytes and that had been backcrossed to the C57BL/6 background >10 times 
(84). The recipient hαIIb+ mice were previously described (89), and are homozygous 
transgenic for hαIIb (hαIIb+/+) that are also null for the expression of platelet mαIIb 
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(mαIIb-/-). These mice platelets express hαIIb levels at ~20% of the level seen on human 
platelets and are functional (90). mUK and hαIIb+ mice were genotyped by polymerase 
chain reaction (PCR) analysis of tail genomic DNA using previously described primer 
pairs and reaction conditions (84, 89). All animal studies were done with Institutional 
Animal Utilization Committee approval at the Children’s Hospital of Philadelphia. 
 
2.3.2 Production of mature megakaryocytes ex-vivo 
Most studies were done with fetal liver (FL-) derived megakaryocytes, beginning with 
E14 FL-cells that were homogenized to a single cell suspension by sequential passage 
through 18, 23, and 25 gauge needles as previously described (91). The cell suspension 
was passed through a 100-µm-nylon mesh filter and cultured in Iscove’s Modified 
Dulbecco’s Medium (IMDM) with 10% calf serum, 2 mM L-glutamine, 1% 
penicillin/streptomycin and 50 ng/ml of recombinant murine TPO (R&D Systems). After 
10 days in culture, over 90% of the resultant cells were megakaryocytes as determined by 
acetylcholinesterase positivity (data not shown). The mature megakaryocyte population 
was isolated using a previously described 2-stage velocity sedimentation method for 
isolating megakaryocytes (92), which involves centrifugation through a 1.5% and 3% 
bovine serum albumin (BSA) gradient at 200 RPMs for 30 min. 
Adult bone marrow (BM-) cells were obtained from femurs and tibiae of C57BL/6 
mice as previously described (93). The cells from the marrow lumen were flushed with 
sterile Dulbecco’s Phosphate Buffered Saline 1X (PBS) (Invitrogen) using a 10-ml syringe 
and a 25-gauge needle. The cells were disrupted and passed through a 100-µm-nylon 
mesh filter. They were then cultured in the same media as the fetal liver cells and 
isolated after 8 days of culture in the same manner. 
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2.3.3 Characterization of ex-vivo derived megakaryocytes 
FL and BM-megakaryocytes to proplatelet number was determined visually with a 
hemocytometer (94). DNA ploidy of the derived megakaryocytes was assessed by flow 
cytometry as previously described (95). Isolated populations were washed with PBS and 
stained with 10-µg/ml monoclonal fluorescein isothiocyanate (FITC)-labeled anti-
murine CD41 antibody (BD Bioscience) for 30 min. The cells were then rinsed twice with 
PBS and resuspended in propidium iodide solution (0.1% sodium citrate with 50 µg/ml 
of propidium iodide) (Sigma) for 4 hrs. The cells were then incubated with 10 U/ml 
RNase A (Sigma) for 90 min at room temperature (RT) and analyzed by flow cytometry 
using a FACScan (Becton Dickinson).  
 
2.3.4 Isolation of platelets and megakaryocytes for infusion 
Washed platelets from whole blood were isolated from the inferior vena cava of C57BL/6 
mice under direct observation and collected into acid citrate dextrose (ACD) as 
previously described (96). Platelet-rich plasma was collected after centrifugation at 200g 
for 5 min at RT, and prostaglandin E1 (Sigma) was added to a final concentration of 1 
mM. Platelets were then pelleted by centrifugation at 800g for 10 min at RT. The pellet 
was washed in calcium free Tyrode’s buffer (134 mM NaCl, 3 mM KCl, 0.3 mM NaH2PO4, 
2 mM MgCl2, 5 mM HEPES, 5 mM glucose, 0.1% NaHCO3, and 1 mM EGTA, pH 6.5), 
and resuspended in CATCH buffer (PBS, 1.5% BSA, 1 mM adenosine, 2 mM theophylline, 
0.38% sodium citrate) (all from Sigma). Platelet counts were determined using a 
HemaVet counter (Triad Associates), and the appropriate amount of platelets was 
infused into recipient mice. Megakaryocytes were produced as described in “Isolation of 
platelets and megakaryocytes ex-vivo”. Once the mature population of megakaryocytes 
was obtained from the BSA gradient, the cells were washed in CATCH buffer and 
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counted with a hemocytometer and infused either retro-orbitally or by tail vein. 
 
2.3.5 Flow cytometric studies in infused hαIIb+ mice  
Before infusion of cells or platelets, whole blood was collected retro-orbitally from 
recipient mice into a mini capillary blood collection tube (RAM Scientific) and again 
afterwards at time points extending from 5 min to 36 hrs. The blood was double stained 
with monoclonal FITC-conjugated mouse, anti-human-specific CD41 antibody 
(eBioscience) and monoclonal phycoerythrin (PE) rat, anti-mouse CD41-specific 
antibody (BD Bioscience) for 30 min and analyzed by flow cytometry using a FACScan. 
Activation of the infused platelets was assessed by 3-color whole blood flow cytometry, 
using a monoclonal mouse anti-human CD41 labeled with peridinin chlorophyll protein 
conjugated with a cyanine dye (PerCP-Cy5.5), PE-rat anti-mouse CD41, and monoclonal 
FITC-rat-anti-mouse P-selectin. To examine the relative expression of membrane 
receptors in recipient versus donor platelets, whole blood was stained with mouse anti-
human CD41 (PerCP-Cy5.5), PE-rat anti-mouse CD41, and either monoclonal antibodies 
FITC-labeled rat anti-mouse GPIbα or rat anti-mouse GPIX (Emfret Analytics). 
 
2.3.6 Infusion studies in thrombocytopenic hαIIb+ mice 
Mice were subjected to a high dose of irradiation (1,000 centigrays total; two sessions, 24 
hours apart). Platelet counts were initially monitored daily to determine a temporal 
platelet profile. Animals included in these studies had platelet counts between 1-2 x 
108/ml on day 7 after irradiation and immediately before infusion of the cells in 200 µl 
CATCH buffer. Additional platelet counts were performed at 4, 24, and 48 hours after 
infusion. 
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2.3.7 Cremaster laser injury functional studies 
Washed platelets and isolated FL-derived megakaryocytes were infused into haIIb+ male 
mice. One hour after infusion, the mice were anesthetized using intraperitoneally 
injected sodium pentobarbital (11 mg/kg, Abbott Laboratories), and maintained under 
anesthesia with the same anesthetic delivered via catheterized jugular vein as described 
(97). Fab fragments from the anti-mouse CD41 antibody were produced using the 
ImmunoPure Fab Preparation kit (Pierce Biotechnologies) and conjugated with Alexa488 
using an Alexa Fluor Protein labeling kit (Molecular Probes). These labeled fragments 
were injected intravenously into the cannulated jugular vein 5 min before injury. The 
cremaster muscle was isolated and the microvessels studied using an Olympus BX61WI 
microscope (Olympus) with a 40X/0.8 numeric aperture (NA) water immersion 
objective lens. Laser injury was induced using an SRS NL100 Nitrogen Laser 
system (Photonic Instruments) at 65% energy level with blood vessels ranging in size 
from 20 to 40 µm. A visual confirmation of small extravasations was made for each 
studied blood vessel as an assurance that the injury was made as well as an indicator of 
consistent injury. Data was collected over a course of 2.5 min at 5 frames per second (f/s; 
750 frames per study). No more than 5 arteriole and 5 venule injuries were done in each 
mouse. 
 
2.3.8 FeCl3 carotid artery injury functional studies  
FeCl3-induced arterial injury was performed as previously described (98) with minor 
changes. HαIIb+ mice were anesthetized by intraperitoneal injection of pentobarbital (80 
mg/kg Nembutal; Ovation Pharmaceuticals) approximately 1 hr after infusion of either 
WT or mUK megakaryocytes. The carotid artery was isolated by blunt dissection, and a 
Doppler flow probe (Model 0.5VB; Transonic Systems) was positioned the 
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around vessel, followed by a 1 x 2 mm2 piece of filter paper (#1; Whatman International) 
soaked in 20% FeCl3 that was placed on the artery for 3 min. The area was then flushed 
with PBS, and blood flow through the artery was monitored for 30 min. Total flow and 
time to the first complete occlusion of >10 min were recorded. 
 
2.3.9 Infused megakaryocyte fate studies 
BrdU studies were carried out to better understand the fate of the infused 
megakaryocytes. FL cells were cultured for 5 days and afterwards exposed to 10 µM 
BrdU (Sigma) in their growth media for 2 more days. The cells were isolated and infused 
into hαIIb+ mice. The mice were sacrificed, and organs, including brain, heart, liver, 
spleen, bone marrow and lungs were dissected at 30 min, 6 hrs, and 24 hrs. The lungs 
were flushed with PBS and inflated with 10% formalin solution (Sigma) to preserve 
alveolar architecture. All organs were fixed in formalin overnight at 4°C for 
immunohistological analysis. Detection of BrdU-labeled nuclei was performed with a rat 
polyclonal anti-BrdU antibody diluted 1/50 (v/v, Abcam) and a biotinylated rabbit 
polyclonal anti-rat IgG diluted 1/200, was used as the secondary antibody. Detection of 
infused megakaryocyte cytoplasm in the lungs was performed by labeling with a goat 
polyclonal antibody against murine αIIb (Santa Cruz biotechnology) and a biotinylated 
rabbit polyclonal anti-goat IgG antibody, diluted 1/200 as the secondary antibody for 
detection was done using a DAKO kit (EnVision). 
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2.4 Results 
 
2.4.1 Infused megakaryocytes and platelets 
To address whether infused megakaryocytes give rise to circulating platelets, we 
generated FL and BM-derived magakaryocytes (Figure 2-1 A). This strategy has been 
described to yield a large number of mature megakaryocytes (91). Mature 
megakaryocytes were separated from other cells and most of the proplatelets by a two-
stage velocity sedimentation to produce a “large cell” fraction with over half of the cells 
having a diameter >50 µm and with only ~2.5:1 pro-platelets:cell (Figure 2-1 B). The 
remaining “small cell” fraction was >95% small megakaryocytes and pro-platelets with 
~10:1 proplatelets:cell (Figure 2-1 B). Ploidy analysis was performed on both fractions 
and showed that the small cell fraction had low DNA ploidy relative to the large cell 
fraction (Figure 2-1 C). 
WT platelets were used as positive controls for studies in which one of the two 
cell fractions of ex-vivo grown FL and BM-megakaryocytes were infused into hαIIb+ mice 
either retro-orbitally or by tail vein; the two approaches gave similar outcomes (Figure 2-
2). The recipient animals have only hαIIb on their platelet surface (89), which allows for 
flow cytometric detection analysis of the infused WT platelets using species-specific anti-
αIIb (CD41) antibodies (Figure 2-3). After infusion, blood derived WT platelets were 
detected in hαIIb+ recipient mice immediately at the 5 min time point (Figure 2-4 A) 
with a half-life of approximately 36 hours (Figure 2-5 A).  
The donor platelets were present in recipient blood as expected based on the 
initial platelet count of the recipient mouse and an estimated blood volume of 2 ml (data 
not shown). After infusing the large cell fractions, donor-derived platelets were seen, but 
with delayed kinetics: only a few donor platelets were detectable at 5 min, 
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followed by a peak at approximately 90 min (Figure 2-4 B and Figure 2-5 A). These 
platelets had a slightly shorter half-life of approximately 20 hrs than when donor 
platelets had been infused. Based on the number of large cells infused, the peak increase 
in platelet count and a recipient mouse blood volume of 2 ml, we calculate that each 
large cell gave rise to 100-200 platelets, assuming all large cells gave rise to platelets. 
Infused small cells, which were richer in proplatelets, gave rise to an immediate peak just 
as infused WT platelets; however, these platelets had a significantly truncated half-life of 
approximately 2 hrs (Figure 2-5 A).  
Infusing adult BM-megakaryocytes grown in culture in the presence of TPO and 
fractionated as in Figure 2-1 B, we were also able to detect circulating platelets. The 
number of platelets per megakaryocyte was similar to FL-derived megakaryocytes, the 
half-life was slightly longer at 24 hrs, but the yield of megakaryocytes from adult marrow 
was lower compared to FL cells. Consequently, further studies below focused on FL-
derived megakaryocytes.  
To simulate clinical thrombocytopenia, we irradiated mice and infused CATCH 
buffer, WT platelets, or FL large cells near the induced platelet nadir and observed that 
both platelets and megakaryocytes significantly increased the platelet count relative to 
CATCH buffer over a time course of more than 24 hours (Figure 2-6). 
 
2.4.2 Characterization of the in-vivo derived platelets from FL-cells 
Platelets derived from the large cell fraction had a shorter half-life than infused platelets. 
The small cell fraction had an even more truncated half-life. We would have anticipated 
that the platelets, especially those from the large cell fraction, (with mostly newly formed 
platelets) would have a longer half-life than infused washed platelets. One clear 
possibility of why FL-derived large cell platelets had a shortened half-life could be that 
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these 
 
 
Figure 2-1. Isolation and characterization of FL-cells. (A) The strategy followed 
in our study is presented by which the three different products for infusion were 
collected: isolated WT platelets, and the large and small cell fractions obtained from FL 
cells grown in the presence of thrombopoietin (TPO). (B) Representative fields of the 
small and large cell fractions. Scale bars: 100 µm. (C) Representative analysis of DNA 
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content of the small and large cell fractions. 
 
 
Figure 2-2. Comparison of retro-orbital Vs tail vein infusions of FL-large 
cells. Flow cytometric percentage of infused ~106 FL-large cells in recipient animals. 
N=5 studies per arm. Mean ± 1 standard deviation (SD) are shown.  
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Figure 2-3. Flow cytometric detection analysis of infused platelets. Flow 
cytometric analysis was performed on whole blood from haIIb+ recipient mice infused 
with WT donor platelets. Gate 1 (platelets) was set up in the forward scatter-H/side 
scatter-H plot (A) representing the overall platelet population. Gate 2 included either 
recipient (anti-haIIb+ FITC) platelets (B) or donor (anti-maIIb+ PE) platelets (C). The 
percentage of the recipient versus donor platelets was calculated from the FL1xFL2 
density plot that included cells satisfying both Gates 1 and 2, as shown in (D). 
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Figure 2-4. Flow cytometric analysis of infused WT platelets, and FL-derived 
megakaryocytes. Flow cytometric analysis on whole blood from hαIIb+ recipient mice 
before and at different time points after retro-orbital infusion of donor cells. Blood was 
stained with labeled species-specific anti-αIIb antibodies. The % of platelets in the left 
upper quadrant represents the recipient’s platelets, while the % in the right lower 
quadrant represents donor-derived platelets. (A) Flow cytometry from recipient mouse 
before and after infusion of 108 platelets (positive control). (B) Flow cytometry from 
recipient mouse before and after infusion of 106 FL-derived large cells. 
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Figure 2-5. Flow cytometric analysis of infused WT platelets, FL and BM-
derived cells on hαIIb+ mice. (A) Flow cytometric percentage of infused 106 FL-large 
cells and (B) infused 106 adult BM-cells. N=5 for WT-platelets, 9 for FL-cells, 5 for BM 
studies. Mean ± 1 SD are shown.  
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Figure 2-6. Flow cytometric analysis of infused WT platelets and FL-derived 
cells in thrombocytopenic mice. Percent platelet rise in irradiated 
thrombocytopenic mice post-infusion. N=5 per arm. Mean ± 1 SD are shown. Initial 
platelet counts (108/ml) in the three groups were: CATCH buffer = 1.8±0.2; platelets = 
1.9±0.3; and large cells = 1.0±0.2. 
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these are fetal platelets which tend to have a shorter half-life then adult platelets (99). To 
see if the half-life improves when using an adult source of megakaryocytes instead of our 
fetal liver derived, we infused cultured adult BM-megakaryocytes, which had a half-life 
perhaps as good as infused WT platelets, but clearly not longer (Figure 2-5 B). Prior 
studies have suggested that a metalloproteinase, tumor necrosis factor alpha-converting 
enzyme (ADAM17), could potentially be present in the media of cultured megakaryocytes 
and be responsible for the shorter half-life, but growing the cells in the presence of either 
metalloproteinase inhibitors GM6001 (Ilomastat) or TAP-1 did not improve the half-
lives (Figure 2-7). 
One indicator of platelet activation would be the presence of donor WT platelet 
microparticles. However, the size-distribution of the platelets derived from the large cell 
fraction was identical to that seen for infused WT-platelets (without a significant pool of 
microparticles by forward scatter) (Figure 2-8). Another indicator of cell activation is the 
expression of P-selectin on the platelet surface (100, 101). Prior studies involving platelet 
concentrate storage and transfusion have shown that this marker is increased on 
activated platelets (102). Flow cytometric analysis did not support platelets derived from 
infused megakaryocytes having a higher level of surface P-selectin expression than 
infused circulating platelets (Figure 2-9 A). Moreover, ADAM17 cleaves the glycocalicin 
extracellular portion of GPIbα, inactivating the GPIb/IX receptor without altering 
surface receptor density (103, 104). We measured relative expression of the extracellular 
portion of GPIbα (Figure 2-9 B) versus GPIX (Figure 2-9 C) on platelets derived from the 
infused large cell fraction as well as from donor washed platelets and found no 
difference. Thus, it appears that the shortened half-life of the platelets derived from 
infused megakaryocytes might not be due to the effects of the previously described ex-
vivo metalloproteinase ADAM17. 
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Figure 2-7. Effect of ADAM17 on thrombopoiesis from in-vitro grown FL-
cells. WT FL-cells were grown in culture in the presence of either 100 µM GM6001 (A 
and B) or 10 µM TAP-1 (C and D) and then separated into small and large cells as in 
Figure 2-2 (B), and infused into hαIIb+ recipient mice to see if these ADAM17 inhibitors 
would improve the half-life observed of platelets derived from infused large cells. N=2, 
performed in duplicates. 
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Figure 2-8. Characterization of the platelets derived from infused cells. (A) 
Size determination of circulating donor platelets from infused platelets or (B) small cell 
or (C) large cell fractions. Shown is a representative study of the forward versus side 
scatter of the whole blood samples measured with the two αIIb positive populations 
highlighted in blue the recipient platelets and in red for the infused platelets or derived 
platelets.  
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Figure 2-9. Characterization of platelets derived from infused FL-cells. (A) 
Representative flow cytometric analysis of P-selectin on infused donor cells resulting 
from either infused platelets or cell fractions. (B) Representative relative levels of GPIbα 
extracellular domain to (C) GPIX in donor platelets from infused platelets or cell 
fractions.  
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2.4.3 Functionality of platelets derived from infused FL-cells 
Clinically, platelets are transfused not to increase platelet number, but to reverse or 
prevent a bleeding diathesis due to the absence of platelets. We have used two distinct 
assays to look at platelet function after infused megakaryocytes. In the cremaster laser 
injury model, we looked at the incorporation of both infused platelets and platelets 
derived from infused large or small cells into growing clots after laser injury to cremaster 
arterioles. In all three settings, donor-derived platelets readily become incorporated into 
the developing thrombi and did so at least to the same extent as for WT donor platelets 
(Figure 2-10 A and B). 
Inclusion of platelets derived from the small cells into growing clots was less 
vigorous. Moreover in this setting, there was a distinct population of CD41+ cells that re-
circulated, rarely becoming incorporated into a thrombus (Figure 2-10 C and D) and 
Supplemental Video 1). This phenomenon was rarely seen after infusion of the large cell 
fraction (Figure 2-10 B) and Supplemental Video 2), and never with infused platelets 
(Figure 2-10 A), and Supplemental Videos 3).  
We also examined platelet function using a FeCl3 carotid artery injury model after 
infusing either CATCH buffer or FL-WT large cells into the hαIIb+ recipient mice. These 
recipient mice have a mild bleeding diathesis in part because of the presence of only 20% 
of the density of CD41 compared to WT mice (89). We found that the infused WT large 
cells lead to a shortened time to development of stable occlusion (5.3 ± 0.5 versus 7.4 ± 
0.9 likely due to the presence of WT donor-derived platelets. We also infused large cells 
grown from the FLs of mice that ectopically express urokinase and store it in their α-
granules (mUK mice) similar to patients with Quebec Platelet Disorder (105). We have 
already demonstrated that mUK mice are resistant to thrombosis in the FeCl3 carotid 
artery injury model and mUK platelets transfused into a WT mouse block clot  
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development (84). We reasoned that if infused large cell fraction-derived mUK platelets 
are functional then they would interfere with clotting in the hαIIb+ recipient mice. 
Indeed, hαIIb+ mice infused with mUK large cells failed to form stable occlusions (Figure 
2-11 A), and total blood flow over the 30 min study was markedly greater in the mUK cell 
infused mice than either control groups (Figure 2-11 B).  
 
2.4.4 Organ distribution studies of infused cells 
The above studies are consistent with the concept that mature megakaryocytes get 
trapped in the pulmonary vasculature and shed functional platelets. Smaller and less 
mature megakaryocytes may be able to escape the pulmonary capillary bed and 
recirculate or get trapped in other organs. To begin to address this model of events, we 
labeled the nuclei of maturing cells in culture by the inclusion of 5-bromo-2-
deoxyuridine (BrdU) in the growth media prior to infusion of the cells, and isolated 
various organs at intervals ranging from 30 min up to 36 hrs. The major staining was in 
the lungs, and this was more intense after infusion of the large cell fraction (Figure 2-12 
A). Stained nuclei were maximal at the first time point checked and were visible for up to 
24 hrs, but not at 36 hrs (Figure 2-12 B). A few nuclei were visible in the red pulp of the 
spleen after both small or large cell fraction infusions (Figure 2-12 C). None were present 
in the liver, heart, brain or bone marrow (data not shown). 
Additionally the BrdU-labeled megakaryocytes appear to retain their cytoplasm 
for up to 30 min post infusion in the microvessels of the lungs (Figure 2-12 B and D). 
This observation would be consistent with the delay seen in peak platelet count after 
infused large cell fraction as seen in Figure 2-4 (B) and Figure 2-5 (A). To confirm this 
observation, we stained the tissues with an anti-murine CD41 antibody and detected 
positive staining cytoplasm present up to 30 min (Figure 2-12 D). 
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Figure 2-10. Platelet incorporation into arterial clots after laser injury. (A-C) 
Representative images of platelets incorporating into clots after infused platelets or 
indicated cells. (A) Donor platelets detected using a labeled anti-mαIIb antibody. (B)/(C) 
Same as (A), but after large and small cells infused, respectively. (D) Sequential stills 
from left to right noting a re-circulating mαIIb+ cell (arrowhead) after small cell infusion. 
(E) Summation of donor platelets incorporated into growing thrombi after either infused 
platelets or cells. Twenty movies were evaluated per graph. 
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Figure 2-11. FeCl3 carotid artery injury studies. (A) Time to stable complete vessel 
occlusion after infused CATCH buffer or WT large cells or mUK large cells. (B) Same as 
in (A), but measurement of total flow over the 30 min study. For (A) and (B), N = 5 per 
arm. Mean ± 1 SD shown for (B).  
 
41
 
 
Figure 2-12. Organ distribution studies of infused FL-cells. (A) Staining of lung 
from haIIb+ mice infused with PBS small or large cells grown in BrdU (arrows point to 
stain nuclei). (A-C) Original magnification = 50X, scale bar = 200 µm. (B) Kinetics of 
BrdU-labeled large cells in the lungs. (C) Same as (A) but for spleen. (D) High power 
(200X) of lungs: BrdU-labeled nuclei (left) and mαIIb (right) 30 min post-infusion of 
large cells. Scale bar = 50 µm. Data are representative of 3 separate studies. 
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2.5 Discussion 
 
Thrombopoiesis is a unique phenomenon developed in mammals to have circulating 
anuclear subcellular fragments that can participate in clot development when the 
circulatory system is perturbed (106). Inherited or acquired disorders of megakaryocyte 
differentiation or cytoskeletal maturation can affect thrombopoiesis and final platelet 
counts (107-110). Understanding thrombopoiesis is important if one is to develop ex-vivo 
methodologies for the production of clinically relevant numbers of platelets. 
While much has been learned about cytoskeletal components in thrombopoiesis, 
it is still unclear where platelets are made and how megakaryocytes shed them. The 
methodology used to study thrombopoiesis has to a large extent defined the potential 
underlying mechanism. Studies of maturing megakaryocytes in culture suggest that a 
mature megakaryocyte forms an interconnected network of “beads-on-a-string” 
proplatelets that could eventually become platelets (33). This model would support in-
vivo thrombopoiesis localized within the marrow space itself. Instead, multiphoton 
intravital microscopy of marrow space suggests that megakaryocytes adjacent to the 
vascular lining shed large cytoplasmic fragments that must then secondarily release final 
platelets within the vasculature (34). Our studies and prior ones that included 
pulmonary histology (35, 36, 38, 39, 86) suggest a third mechanism wherein normal 
sized and functional platelets are released from circulating, mature, high-ploidy 
megakaryocytes directly within the vascular bed. These models are not necessarily 
mutually exclusive: Large cytoplasmic fragments may be the norm, while whole 
megakaryocytes are less frequently released into the circulation. Both large cytoplasmic 
fragments and whole megakaryocytes may shed platelets within the pulmonary bed 
using mechanisms consistent with the in- vitro studies, but with concurrent flow 
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and local vascular factors involved as others have proposed (111).  
Intuitively, one would expect that megakaryocytes lodging in the lungs might 
pose a cardiovascular challenge. However, if a mouse has 1-2 X 109 platelets and these 
have a half-life of 5 days (112), and if a megakaryocyte sheds 102 platelets, then one 
would need 2-4 X 106 megakaryocytes each day traveling to the lungs to maintain the 
animal’s platelet count. We infused 106 megakaryocytes in most of our studies, and while 
death as an endpoint was not measured (all arms of our studies had some animal losses, 
but no one arm was particularly harmful), infusing what is near to a daily number of 
needed megakaryocytes over a 10 min period was tolerated. Since the mouse has 2.3 x 
106 alveoli in both lungs (26), and each alveolus is traversed by many capillaries (25-100; 
based on human alveolar structure, corrected for the difference in volume between 
human and murine alveoli (113), our calculation is that each mouse lung contains 
approximately 108 capillaries, which is well with in the estimates of 4 x1011 capillaries for 
the human lung (113). Given this number of capillaries, we anticipate that we are 
blocking ~1% of pulmonary capillaries for up to 24 hrs from our kinetic studies in Figure 
2-11 (Table 2-1). 
In addition to the pulmonary vasculature having the capacity to handle an influx 
of megakaryocytes, another question is whether the pulmonary vasculature offers a 
special niche for platelet release. Would megakaryocytes get trapped in other vascular 
beds and if so would they be as efficient in thrombopoiesis? Clearly a few 
megakaryocytes reached and were trapped in the splenic red pulp, but whether these 
megakaryocytes can shed platelets is unclear, even though some suggest that this is also 
a site for platelet production (114). Individuals with significant right to left 
cardiovascular shunts are known to have lower platelets counts, which others have 
proposed to be due to pulmonary bypass by circulating megakaryocytes (115). However,  
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Table 2-1. Calculation of number of alveoli capillaries blocked by infused 
megakaryocytes. 
Mice platelet content: 1-2 X 109 platelets (112) 
Mice platelet half-life: 37 hrs (118) 
Megakaryocyte sheds 102 platelets (determined in this study). 
Calculate: 2-4 X 106 megakaryocytes each day traveling to the lungs to maintain the 
animal’s platelet count.  
 
Mice alveoli: 2.3 X 106 in both lungs (119) 
Capillaries per alveoli: 25-100; based on human alveolar structure, corrected for the 
difference in volume between human and murine alveoli) (113) 
Calculate: Infusion of = 106 megakaryocytes over 10 mins into the mice will block 0.4-
1.7% of the entire capillary bed for a 24 hr period.  
 
 
FL-derived megakaryocytes that naturally bypass the pulmonary bed can form platelets 
(116, 117), suggesting that other vascular beds may be able to substitute for the 
pulmonary vasculature. 
We have shown that the formed platelets from infused megakaryocytes are 
normal in size, without a significant number of microparticles (Figure 2-8), and without 
notable activation (Figure 2-9 A) or extracytoplasmic cleavage of surface GPIbα (Figure 
2-9 B and C). Moreover these formed platelets can be actively incorporated into growing 
thrombi Figure 2-10. However, why these derived platelets have a slightly shorter half-
life than infused, isolated platelets is unclear. We anticipated that platelets derived from 
megakaryocytes would be newly generated with a prolong half-life. 
Whether the shortened half-life has to do with the in-vitro culture necessary to 
grow the megakaryocytes is unknown. Previously, it had been suggested that 
metalloproteinase ADAM17 is present in the media and affects platelet half-life (120). 
Our studies showed no loss of at least one of the targeted surface marker by the 
metalloproteinase and using the same inhibitors to block ADAM17 as previously 
described did not alter the half-life of the platelets formed from infused large 
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megakaryocytes (Figure 2-7). An alternative explanation for the shortened half-life to the 
in-vitro culture conditions is that most of our studies were done with FL-derived 
megakaryocytes and fetal platelets have a shortened half-life compared to adult platelets 
(99). However, platelets derived from grown adult marrow megakaryocytes also had a 
relatively short half-life than infused, donor-derived platelets. There are insufficient 
numbers of primary megakaryocytes in isolated adult marrow to test whether these cells 
would have a longer half-life. 
Our demonstration that infused megakaryocytes can form a significant number of 
functional platelets may be of clinical importance. In-vitro generation of a large number  
of biologically responsive platelets has remained problematic. The best-published 
outcome for in-vitro formed platelets resulted with levels of platelets that are at least two 
orders of magnitude lower compared to what we have been able to achieve with infused 
megakaryocytes. Our studies open the possibility that if one can establish a cell line that 
can be expanded and differentiated into mature megakaryocytes then one might be able 
to infuse these megakaryocytes as a non-donor dependent source of platelets. Such a line 
had been described for mice, G1ME cells (121). These cells can be repeatedly derived 
from a GATA-1 deficient embryonic stem cell line and that upon restoration of GATA-1 
goes on to form ~50% megakaryocytes (121). Moreover, modification of such lines to 
ectopically express a protein of interest during megakaryopoiesis may be useful for the 
targeted delivery of such a protein to sites of vascular injury as described by us for the 
delivery of coagulation factor VIII for the treatment of hemophilia A and urokinase for 
targeted fibrinolysis (84, 122). This additional benefit of generating platelets in-vivo 
from infused modified megakaryocytes is supported by our data in Figure 2-11 that 
shows that urokinase delivery to thrombi is a potential benefit of our approach using 
mUK FL-derived megakaryocytes that ectopically express urokinase and store this 
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protein in α-granules as they mature.  
In summary, we have addressed whether infused megakaryocytes can release 
platelets within the pulmonary bed and demonstrated that biologically active platelets 
can be formed in-vivo with characteristics similar to those of normal platelets. The 
process is vigorous, and enough platelets are formed so that platelet count can be 
boosted and hemostasis can be improved and modified by targeted delivery of ectopic 
proteins. Based on our estimate of 100–200 platelets generated per infused 
megakaryocyte, the challenge is to generate 109 mature WT or modified megakaryocytes 
expressing and storing an ectopic protein of interest to achieve a 10% rise in platelet 
count in an average 70-kg patient. 
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Table 2-2. Supplemental movie legend 
Video 1. Incorporation of donor platelets in arteriole thrombi of hαIIb+ 
recipient mouse after infusion of FL- small cells, following laser injury. As in 
Figure 2-10 (C) with an injury created near the center of the video and blood flow from 
top to bottom on the screen. The platelets depicted in green were detected with an anti-
mouse CD41 antibody labeled with Alexa488. Incorporation of platelets from small cells 
into the thrombi was seen with a distinct population of CD41+ cells re-circulating and 
rarely incorporated into the growing thrombus. 
Video 2. Incorporation of donor platelets in arteriole thrombi of hαIIb+ 
recipient mouse after infusion of FL-large cells, following laser injury. As in 
Figure 2-10 (B) with an injury created near the center of the video and blood flow from 
top to bottom on the screen. The platelets depicted in green were detected with an anti-
mouse CD41 antibody labeled with Alexa488. Incorporation of platelets from the large 
cells into the growing thrombi was detected similar to infusion of WT platelets. 
Video 3. Incorporation of WT donor platelets in arteriole thrombi of hαIIb+ 
recipient mouse following laser injury. As in Figure 2-10 (A) with an injury 
created near the center of the video and blood flow from top to bottom on the screen. 
The platelets depicted in green were detected with an anti-mouse CD41 antibody labeled 
with Alexa488. Incorporation of the WT infused platelets into the growing thrombi was 
clearly detected. 
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Chapter 3 
Platelet-targeted pro-urokinase as a novel 
thromboprophylaxis fibrinolytic strategy 
 
 
3.1 Abstract 
 
Use of plasminogen activators (PAs) is restricted to life-threatening thrombotic 
conditions because high concentrations are required to diffuse into clots in order to 
overcome PA inhibitors and compensate for rapid clearance, that can lead to bleeding. 
We hypothesized that targeting pro-PAs to platelets would circumvent these obstacles 
and preferentially lyse nascent, pathological clots that are actively recruiting platelets, 
while sparing preformed hemostatic clots and also avoiding systemic fibrinolysis. To test 
this concept, we produced a chimeric protein by fusing a scFv from an anti-hαIIb 
monoclonal antibody (moAb) 312.8 linked to a thrombin activatable uPA-T, which we 
reasoned would be activated preferentially at sites of active clot propagation. Anti-PLT 
scFv/uPA-T expressed in Drosophila S2 insect cells bound specifically to human and to 
hαIIb+ mouse platelets, but not to WT. Anti-PLT scFv/uPA-T bound specifically to 
immobilized hαIIbβ3 protein with a Kd of ~80 nM, and retained its zymogenic 
properties until activated specifically by thrombin. The fibrinolytic activity of anti-PLT 
scFv/uPA-T and the non-targeted counterpart uPA-T were analyzed in two mouse 
models of vascular thrombosis. In the FeCl3 carotid artery injury model hαIIb+ mice were 
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protected from forming occlusive thrombi for at least 10 hrs post-injection of anti-PLT 
scFv/uPA-T whereas even five-fold higher concentrations of uPA-T were effective for 
only 2-5 min. In the cremaster arteriole injury model hαIIb+ mice show a significant 
reduction in both fibrin deposition and platelet accumulation even after 5 hr of anti-PLT 
scFv/uPA-T infusion, which was not seen after infused uPA-T or PBS. These studies 
support another novel approach to that in Chapter 2 using modified megakaryocytes for 
prophylactic targeting drug delivery by combining a pro-drug that requires activation by 
thrombin with platelet delivery to sites of incipient thrombotic vascular occlusion.  
 
 
3.2 Background 
 
Thrombosis is the major cause of death and disability in the U.S. (80, 123). Occlusive 
thrombi impairs blood flow to vital organs causing local oxygen deprivation, tissue 
necrosis and organ dysfunction. PAs and direct thrombin inhibitors are effective acutely, 
but are associated with substantive risks of bleeding and are not formulated for 
thromboprophylaxis. No agent prevents thrombosis in the majority of patients and all 
increase the risk of bleeding, in large part because they act systemically. In theory, a 
more ideal thromboprophylactic agent would have the following properties: 1) circulate 
as a prodrug, 2) target incipient thrombi, while sparing hemostatic clots, and 3) remain 
amenable to regulation. 
PAs are not used for prophylaxis due to their rapid clearance and hemorrhagic 
and neurotoxic side effects. All existing PAs are small, short-lived (<30 min) molecules 
capable of diffusing into hemostatic clot, which may cause bleeding.  PAs can also diffuse 
into the CNS where they may cause collateral damage, and therefore are not 
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suited for use as prophylaxis in post-surgical or other patients at imminent risk of 
thrombosis. We hypothesized that coupling PAs to a longer-lived carrier that is confined 
to the blood and has a natural targeting mechanism to sites of thrombus formation will 
block PA diffusion into hemostatic mural clots and the CNS, limiting its adverse effects, 
while being retained in the blood, prolonging the intravascular effect, and thus 
permitting use as prophylaxis. We propose using a platelet-delivery strategy to target 
incipient or ongoing pathological clotting. To do so, we developed a recombinant fusion 
protein composed of a scFv of a moAb (Figure 3-1) against the haIIb subunit of the 
platelet integrin receptor aIIbb3 (GPIIb/IIIa, CD41a) and a thrombin-activatable low 
molecular weight- single-chain urokinase plasminogen activator (lmw-scuPA), which has 
been designated uPA-T (Figure 3-2).  
 
 
3.3 Material and methods 
 
3.3.1 Analysis of anti-hαIIb moAbs 
Various anti-platelet moAbs were analyzed to check their binding specificity to WT, 
hαIIb+ mice and human platelets by flow cytometry (Figure 3-5) (generously provided by 
Dr. Richard Aster and Dr. Daniel Bougie from the monoclonal laboratory of the Blood 
Research Institute, Milwaukee, WI). The moAb (312.8) that we end up using in our 
studies has been previously characterized (124). Murine platelets were isolated from the 
inferior vena cava as described in “2.3.4 Isolation of Platelets and Megakaryocytes for 
Infusion”. Human platelets were isolated from 10 ml of fresh blood, and platelet rich 
plasma (PRP) separated after centrifugation at 200g for 10 min at room temperature 
(RT). The platelets were then isolated from PRP in the same manner as describe for 
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Figure 3-1. Final construct proposed. The anticipated final construct is shown on 
the right and would consist of a single-chain version of uPA that contains a thrombin 
cleavage site uPA-T. Upon thrombin proteolysis, uPA-T would activate plasminogen to 
plasmin and lead to clot lysis via fibrinolysis. The uPA-T will be fused at its N-terminus 
to an scFv derived from a moAb (shown on left) that binds in a specific fashion to the 
surface of human platelets via the αIIb receptor 
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Figure 3-2. Molecular design of uPA-T. Thrombin-inducible lmw-scuPA was 
generated by deleting Phe157 and Lys158, which converts the plasmin activation site into 
one that is cleave by thrombin after Arg156. 
 
 
 
 
 
 
 
53
murine platelets. Total washed platelets were counted on a Hemavet cell counter 
(Triad Associates), resuspended in aliquots with a final concentration of 3x108/ml. 
Platelets suspensions were incubated with corresponding moAbs (0.1 mg/ml) for 1 hr at  
37ºC. Unbound moAb was washed with PBS prior to incubating with a secondary 
polyclonal Ab, FITC-goat anti-mouse IgG (BD Bioscience) for 30 min and analyzed by 
flow cytometry using a FACScan. 
 
3.3.2 Platelet aggregation of anti-hαIIb moAbs 
Platelet aggregation studies were performed as previously described (98), Briefly human 
PRP was adjusted to 3X105 platelets/µl with platelet-poor plasma (PPP). Samples of PRP 
were either untreated or incubated for 5 minutes at 37°C with 20 µg/mL of moAb. 
Platelet aggregation was induced by adding to PRP adenosine diphosphate (ADP) at 5 
µM, and light transmission was measured over time in an aggregometer (Kowa AG-10E; 
Kowa) while stirring.  
 
3.3.3 Construction and expression of anti-PLT scFv/uPA-T 
Construction of the Anti-PLT scFv/uPA-T was performed following techniques used for 
fusing plasminogen activators with serine-rich linker peptides, with some modifications 
(85, 125, 126). Total RNA isolated from the moAbs hybridoma cell lines was reverse 
transcribed (RNeasy, Qiagen) using SMARTTM technology (Clontech) employing primer 
combinations described previously (127). The heavy and light chain variable fragments 
were clone into TOPO vectors (Invitrogen) (Figure 3-3) and positive clones were 
sequenced analyzed. The fragments were constructed using standard nested-PCR 
methodology, in which the variable heavy (Vh) fragment was amplified with an 
xxxxxxxxx 
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Figure 3-3. Depiction of the strategy to generate the anti-PLT scFv. The 
schematic diagram depicts the strategies undertaken to produce the anti-PLT scFv 
fragment as detailed in the Methodology. 
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Figure 3-4. Depiction of the strategy to generate the anti-PLT scFv/uPA-T. 
The schematic diagram depicts the strategies undertaken to produce the final construct, 
which was used to produce the fusion protein anti-PLT scFv/uPA-T as detailed in the 
Methodology. 
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outer primer (Vh-FWD 5’- tgc atg tgc atg cca tgg cag tca ggg gga ggc-3’) and a reverse 
primer that introduced a linker (GGGGS)3 (128) at the end of the fragment (linker rev 5’-
gat tgc tgg aga ttg agt gag cac gct gcc acc acc gcc gct gcc acc acc gcc gct gcc acc acc gcc ggg 
tgt cgt ttt ggc tga gga gac-3’). The variable light (Vl) fragment was amplified with a 
complementary primer to “linker rev” (linker FWD 5’-gtc tcc tca gcc aaa acg aca ccc ggc 
ggt ggt ggc agc ggc ggt ggt ggc agc ggc ggt ggt ggc agc gtg ctc act caa tct cca gca atc-3’) and 
a downstream primer (Vl rev 5’- tcc ccg cgg agt tgg tgc agc atc-3’). Joining of both 
fragments was completed by using the same outer primer “Vh FWD” that contains a 
restriction site for NcoI at the 5’ end, and the downstream primer “Vl rev” which 
introduces a restriction site for SpeI at the 3’ end in order to clone into insect expression 
vector pMT/BiP/V5-His B (Invitrogen) (Figure 3-7 A). The anti-PLT scFv PCR products 
were purified and digested with NcoI and SpeI restriction enzymes, (New England 
BioLabs) ligated and cloned into the NcoI and SpeI sites of the insect vector. Successful 
cloning was confirmed by restriction analysis of plasmid and by automated DNA 
sequencing (NAPCORE, The Children’s Hospital of Philadelphia). We then established a 
stable S2 drosophila cell line (Invitrogen) expressing the anti-PLT scFv (Figure 3-7 C) 
and analyzed the protein for binding to hαIIb from the insect media by ELISA (Figure 3-
8) and flow cytometry (Figure 3-9).  
To produce the complete chimeric protein construct, nested-PCR was performed 
(Figure 3-4) to link the two fragments scFv and uPA-T.  The fragment for the scFv 
portion was amplified with primer “Vh Fwd” and a new primer that introduce a linker 
(SSSSG)2 (128) downstream of the scFv (linker rev 5’-agt ctt ttg gcc aca ctg aaa ttt taa gcc 
gga aga gct act acc cga tga gga aga agt tgg tgc agc atc agc ccg ttt tat ttc ca- 3’). The uPA-T 
fragment was amplified with a complimentary long primer to the “linker rev” (5’-tgg aaa 
taa aac ggg ctg atg ctg cac caa ctt ctt cct cat cgg gta gta gct ctt ccg gct taa aat ttc agt gtg gcc 
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aaa aga ct-3’) and an outer primer (uPA-t rev 5’-cca atg cat tgg ctc gag tca tca ctt gtc atc 
gtc atc ctt gta atc gat-3’). 
To join both fragments once again outer primer “Vh Fwd” which contain a 
restriction site for NcoI at the 5’ end was used, and the downstream primer “uPA-T Rev” 
which introduces a restriction site for XhoI at the 3’ end as well as a three flag tag with a 
stop sequence (Figure 3-7 B). The restriction sites were introduced to clone into insect 
expression vector pMT/BiP/V5-HisA. Stable drosophila cell line expressing the anti-PLT 
scFv/uPA-T was established for production of the protein. The proteins were purified 
from cell media by affinity chromatography using an M2 (anti-flag) affinity column 
(Sigma) followed gel filtration chromatography on Sephacryl SHR100 column 
(Amersham) to greater than 95% purity, which was confirmed by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 3-10 A and B) with a 
yield approximately 3 to 5 mg/L medium. Proteins were concentrated in PBS to 2 
mg/mL, separated into aliquots and stored at -80°C. 
 
3.3.4 Biochemical characterization of anti-PLT scFv/uPA-T 
Characterization of the protein was performed in the same manner as previously 
described for other scFv chimeric proteins (126). The size and homogeneity of the fusion 
protein was analyzed using a 4%-12% gradient SDS-PAGE and Western blotting (Figure 
3-10 C). For Western blot analysis, the separated proteins were transferred to a 
nitrocellulose membrane (Invitrogen) blocked with tris(hydroxymethyl)aminomethane 
(Tris)-buffered saline containing 10% non-fat milk powder and 0.1% Tween–20. The 
fusion protein was detected using a 1:1000 dilution of a horseradish peroxidase (HRP) 
conjugated anti-flag tag moAb (Sigma). The antigen-antibody complex was detected with 
ECL Plus (Amersham). 
The intrinsic and thrombin-induced activities of anti-PLT scFv/uPA-T were 
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measured using casein zymography. Anti-PLT scFv/uPA-T, (10 ng) intact or pre-
incubated with 20 nM thrombin, were mixed with non-reducing Tris-glycine SDS sample 
buffer prior to zymography. The samples were resolved on a 7.5% gel cast with 10% non-
fat dry milk and 20 µg/ml plasminogen to detect PA activity (129). The gels were re-
natured in Novex zymogram renaturating buffer (Invitrogen) and developed in Novex 
zymogram developing buffer (Invitrogen) per the manufacturer. EDTA (5 mM) (Sigma)  
 
3.3.5 Binding of anti-PLT scFv/uPA-T to hαIIbβ3 
Binding specificity of the anti-PLT scFv/uPA-T to hαIIbb3 was analyzed with platelets 
using flow cytometry techniques and the methodology described in “3.3.1 Analysis of 
anti-hαIIb monoclonal antibodies”. The specificity of the fusion protein was also 
analyzed with plastic immobilized hαIIbhβ3 in 2 modes: by standard ELISA (Figure 3-12 
A) or with 125I-labeled anti-PLT scFv/uPA-T (Figure 3-12 B). HαIIbhβ3 protein (Enzyme 
Research) was immobilized on high-binding plastic 96 well plates (Corning) at 1 µg/well. 
Non-specific binding was blocked by 5% PBS/BSA for 1 hr at 37°C then washed with 
PBS/0.1% Tween20 (PBS/Tween). For standard ELISA, various concentrations of anti-
PLT scFv/uPA-T, uPA-T, or a non-specific fusion protein anti-GPA scFv/uPA-T were 
incubated for 1 hr at 37°C. After washing with PBS/Tween, an anti-flag HRP conjugated 
moAb served as the primary antibody. The antigen-antibody complex was detected with 
3,3',5,5'-tetramethylbenzidine (TMB) peroxidase substrate (Amersham) and absorbance 
was measures at 490nm. For the second method, the fusion protein was radio labeled 
with 125I-Na (Perkin Elmer) in Iodination tubes (Thermo Scientific). After blocking with 
5% PBS/BSA and washing with PBS/Tween, various concentrations of the labeled 
chimeric protein (100 µl/well) were incubated with hαIIbhβ3 or BSA coated wells for 1 hr 
at 37°C. Immobilized BSA served as a negative control.  Non-bound material 
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was removed by washing with PBS/Tween and residual radioactivity was measured on a 
γ-counter (Perkin Elmer). 
 
3.3.6 In-vitro fibrinolysis of anti-PLT scFv/uPA-T 
Bovine fibrinogen (Sigma) was dissolved in PBS to a final concentration of 3 mg/ml. 
Clotting was induced by addition of CaCl2 and thrombin (Sigma) (20 mM and 0.2 
units/ml final concentrations, respectively) and the resulting solution was immediately 
added to 24 well cell culture plate (0.75 ml/well) where clots were formed and allowed to 
maturate for 30 min. Anti-PLT scFv/uPA-T was activated by incubation with 20 nM 
bovine thrombin (Amersham) for 1 hr and serial dilutions (50 µl/well) were added on top 
of each clot at 37°C. Lytic zones were measured after 12 hr incubation. 
 
3.3.7 Effect of anti-PLT scFv/uPA-T in models of vascular thrombosis 
Studies were done on male hαIIb+ mice as described in “2.3.7 Cremaster laser injury 
functional studies”. The timing, spatial and absolute incorporation of fibrin and platelets 
into the growing thrombi were followed using a specific anti-fibrin antibody and an anti-
species-specific αIIb Ab, respectively that do not interfere with clot growth.  
For FeCl3 studies, we used the strategy as described in “2.3.8 FeCl3 carotid artery 
injury functional studies”. Briefly, 1 mg/kg of anti-PLT scFv/uPA-T or 1 mg/kg uPA-T 
was injected IV into hαIIb+ mice prior to FeCl3-induced carotid artery injury. 
Administration of PBS served as the negative control. Occlusion and total blood flow was 
monitored by Doppler ultrasound probe. Both proteins and PBS were injected 10 mins to 
10 hrs prior to arterial injury to estimate the therapeutic window of thromboprophylaxis 
and blood flow after injury was monitored for over 30 min. 
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3.3.8 Future studies with the anti-PLT scFv/uPA-T fusion protein 
Effect of anti-PLT scFv/uPA-T fusion protein on platelet activation. To analyze if 
anti-PLT scFv/uPA-T promotes activation of isolated platelets, flow cytometry will be 
performed as described (130) with minor modifications. Platelets from hαIIb+ mice will 
be prepared and aliquot will be incubated with saturating concentrations of anti-PLT 
scFv/uPA-T. Unbound protein will be removed by washing. As a positive control, a 
subset of intact platelets will be stimulated with the weak activator ADP (25 mmol/L) or 
buffer control. Fusion protein-coated platelets will be handled in the same manner. 
Platelets from each experimental group will be fixed and washed. The platelets will be 
stained with R-phycoerythrin (PE)-labeled P-selectin-antibody (mouse IgG, CLB), mouse 
moAb PAC-1 (Becton Dickinson), which recognizes only the activated form of mouse 
αIIbβ3, or an equivalent concentration of unspecific IgG and binding will be measured 
using a FACScan (131).  
Effect of anti-PLT scFv/uPA-T on platelet aggregation. To further assess the 
effect of the fusion proteins on platelet function, platelets from hαIIb+ mice will be 
incubated with saturating concentrations of anti-PLT scFv/uPA-T and the unbound 
protein will be removed by washing. Aggregation in response to a weak agonist will be 
measured using a platelet aggregometer as described (132). WT and unactivated fusion-
coated hαIIb+ murine platelets will serve as negative controls. 
Pharmacokinetics of anti-PLT scFv/uPA-T vs. uPA-T. Anti-PLT scFv/uPA-T and 
uPA-T will be labeled with 125I and tracer amounts will be injected via the jugular vein of 
WT and hαIIb+ mice. Blood clearance and misdistribution of the injected protein 10 min, 
60 min, 3, 6, 24, 48, and 72 hrs after infusion will be measured. The animals will be 
sacrificed and major organs (lungs, liver, kidneys, spleen, heart, brain) will be harvested 
and perfused free of blood. PRP will be isolated and centrifuged at 104g to separate 
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platelets from PPP. All blood fractions and organs will be analyzed for radioactivity and 
distribution of injected labeled proteins will be determined (% of injected dose and % of 
injected dose/g tissue).  
Platelet counts will be measured to determine whether anti-PLT scFv/uPA-T 
affects platelet lifespan. To verify that platelet half-life is not affected by the chimeric 
protein in vivo, we will incubate hαIIb+ mouse platelets with the fluorescent dense 
granule marker mepacrine (quinacrine) (133) and the fusion protein subsequently 
infused into hαIIb+ mice. Survival of the infused platelets can then be detected by flow 
cytometry at different time points after infusion.  
We will also determine the desorption kinetic of 125I anti-PLT scFv/uPA-T from 
hαIIb+ platelets. Washed platelets will be incubated with 125I anti-PLT scFv/uPA-T and 
injected into WT or hαIIb+ mice. Blood and major organs will be collected as above and 
the distribution of residual radioactivity will be measured over time. The half-life of the 
fusion protein loaded platelets will be determined using the Vybrant CFDA SE Cell 
Tracer kit (Molecular Probes) as previously described (134). 
Retention of anti-PLT scFv/uPA-T and uPA-T fibrinolytic activity during 
circulation in blood. We will follow the protocol described previously for a prototype 
RBC/tPA conjugate (135, 136). Briefly, equimolar amounts of anti-PLT scFv/uPA-T, 
uPA-T or PBS will be injected intravenously (IV) into anesthetized WT and hαIIb+ mice. 
At pre-designated times determined above, aliquots of blood will be drawn in the 
absence of anticoagulant, mixed rapidly with trace 125I-fibrinogen and allowed to clot. 
Clots will be overlaid with PBS and incubated at 37°C for 24 hrs and the release of 125I 
will be measured as above. These experiments will allow us to estimate the relationship 
between the dose, magnitude and duration of fibrinolytic activity of anti-PLT scFv/uPA-
T in the circulation. 
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Depletion of fibrinogen by circulating anti-PLT scFv/uPA-T or uPA-T. We will 
follow the protocol described previously for a prototype uPA-T fusion protein directed to 
endothelium (85). Equimolar amounts of anti-PLT scFv/uPA-T, uPA-T or PBS, in 
amounts based on the blood fibrinolytic activity determined above, will be injected IV 
into WT and hαIIb+ mice. At pre-designated times based on the measured circulation 
time and blood activity, blood will be drawn in citrate and PPP. Plasma fibrinogen will be 
measured by ELISA using a standard curve based on purified mouse fibrinogen. 
Bleeding after administration of anti-PLT scFv/uPA-T fusion protein. We will use 
the tail re-bleeding time as an initial test of hemostasis in treated WT and hαIIb+ mice 
(137, 138). To evaluate hemorrhagic potential, mice will be anesthetized, equal doses 
(determined in ex-vivo blood clot lysis experiments) of anti-PLT scFv/uPA-T or uPA-T 
will be injected 10 min to 72 hrs prior to analysis. Tails will be immersed in a water bath 
at 37°C for 5 min, a 5-mm terminal segment will be amputated, and the time required to 
stop bleeding will be determined visually and the amount of released hemoglobin will be 
measured. After the initial bleeding has stopped, re-bleeding will be evaluated by 
immersing the tail in 4 ml of 37°C PBS containing 14 mmol/L tri-sodium citrate for 1 hr. 
The number of RBC and the amount of hemoglobin released in PBS will be determined 
to quantify blood loss (137, 138). To elucidate whether platelet-bound anti-PLT 
scFv/uPA-T will spare hemostatic clots better than uPA-T, re-bleeding will be measured 
as above, with the exception of injecting the proteins after spontaneous bleeding has 
ceased before evaluating re-bleeding.  
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3.4 Results 
 
3.4.1 Binding analysis of anti-platelet moAbs  
Binding of multiple anti-hαIIb moAbs (generously shared by Drs. Daniel Bougie and 
Richard Aster, Blood Center of Wisconsin) was verify against WT, hαIIb+ mice, and 
human platelets and analyzed by flow cytometry. Many of the antibodies bound with 
significant affinity to the surface of human platelets (Figure 3-5) and hαIIb+ mice 
platelets (not shown), but none to WT platelets (not shown). Two moAbs with high 
affinity to human platelets were chosen for further analysis (Abs 184.2 and 312.8) (124). 
The antibodies were analyzed to see if they interfere or enhance platelet aggregation. As 
it can be seen in Figure 3-6, moAb 184.2 altered aggregation, whereas moAb 312.8 may 
have slightly inhibited aggregation. Both were further studied understanding that there 
level of surface aIIbb3 receptor is dense and at low moAb concentrations, most receptors 
may still be available for ligand binding. 
 
3.4.2 Binding analysis of anti-platelet scFv  
Construction of the fusion protein was undertaken with both moAbs (184.2 and 312.8) 
by isolating RNA from their hybridoma cells and performing RT-PCR to form heavy and 
light variable fragments by a nested PCR strategy as depicted in Figure 3-3. The resultant 
heavy and light chain variable fragments were assembled to form the anti-PLT scFv 
(Figure 3-7 A). The purified PCR product was cloned into an insect vector and expressed 
in Drosophila S2 cells and expression confirmed by immunoblotting with anti-V5-HRP 
moAb (Figure 3-7 B). The overall construct was formed with the same PCR strategy 
(Figure 3-4) where the scFv segment was joined with a uPA-T (Figure 3-7 C). Binding of 
x  
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Figure 3-5. Binding analysis of anti-hαIIb specific moAbs to human platelets. 
Human platelets were incubated with 0.1 mg/ml of different anti-platelet moAb’s and 
stained with an anti-mouse-FITC conjugated Abs. Mean fluorescence of 105 platelets was 
measured. Only the two moAbs pursued further are noted. The binding to secondary 
antibody alone is shown as the gray-fill graph. Details of the procedure are in the 
Methodology. 
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Figure 3-6. Platelet aggregation analysis of anti-hαIIb specific moAbs. The 
two chosen moAbs were studied further using platelet aggregation studies with human 
PRP as detailed in the Methodology. Monoclonal Abs were added at 20 µg/mL and ADP 
activation was at 5 µM at point indicated (see arrows).  
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Figure 3-7. Generating the anti-PLT scFv/uPA-T fusion construct. The general 
construct strategies are shown in Figures 3-3 and 3-4. (A) Agarose size fractionation gel 
of the assembled scFvs with expected size of 735 base pairs. (B) Western blot analysis of 
native culture medium from S2 cells transfected with anti-PLT scFv expression plasmid 
after induction with 0.5 mM CuSO4. An HRP-moAb against the flag tag served as the 
detecting antibody, showing expression of the expected scFv chimera proteins (C) Same 
as (A), but for the scFvs assembled with a uPA-T fragment into full-length anti-PLT 
scFV/uPA-T with expected size of 1640 base pairs.  
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both anti-PLT scFv’s to immobilized hαIIbhβ3 protein was confirmed by ELISA (Figure 
3-8). When analyzing binding by flow cytometry, anti-PLT scFv 312.8 bound to human 
and hαIIb+, but not WT, mouse platelets (Figure 3-9 A). Anti-PLT scFv 184.2 bound to 
human platelets with less affinity (Figure 3-9 A), and it did not bind to hαIIb+ or WT 
mouse platelets (Figure 3-9 B and C). 
 
3.4.3 Analysis of anti-platelet scFv/uPA-T 
After establishing stable drosophila S2 cell lines expressing anti-PLT scFv/uPA-T, both 
proteins were purified from cell media by affinity chromatography using an M2 (anti-
FLAG) affinity column (Figure 3-10 A and B). To confirm that the fusion proteins 
retained the antigen recognition properties of the parental moAb and scFv, flow 
cytometry studies were performed. Anti-PLT scFv/uPA-T 312.8 bound to human 
platelets as well as hαIIb+ but not WT mice platelets (Figure 3-11). The binding was  
similar to what was demonstrated by its scFv. Interestingly, anti-PLT scFv/uPA-T 184.2 
appears to have lost its affinity since it did not recognize human or hαIIb+ mouse 
platelets, in contrast to its scFv, likely due to the chimeric construct decreasing affinity of 
the scFv for hαIIb (Figure 3-11). Therefore, future studies focused on the fusion protein 
312.8, and is referred to below as anti-PLT scFv-uPA-T. 
To further show the specificity of anti-PLT scFv/uPA-T we performed the experiment on 
plastic immobilized hαIIbβ3 in two modes: with standard ELISA (Figure 3-12 A) and 125I-
labeled fusion protein (Figure 3-12 B). Both methods exhibited specific and dose-
dependent binding of anti-PLT scFv/uPA-T to the antigen with a Kd of ~80 nM. 
Moreover, labeling with iodine did not influence the affinity of the fusion protein, which 
should simplify future pharmacokinetic experiments. 
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Figure 3-8. ELISA analysis of moAbs and scFv induced and non-induced S2 
media. ELISA of hαIIbhβ3 protein coated platelets with the original indicated moAb or 
scFv S2 insect cell media. Mean ± 1 SD are shown. N = 3, each done in duplicate. 
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Figure 3-9. Characterization of anti-PLT scFv. (A) Human, (B) haIIb+ mouse and 
(C) and WT mouse platelets were incubated with 0.1 mg/ml of  312.8 anti-PLT scFv 
(red), moAb 312.8 (red) or 184.2 anti-PLT scFv (green), and moAb 184.2 (green) for flow 
cytometric studies of binding. Grey-filled in curve is secondary only binding. Mean 
fluorescence of 105 platelets was measured for each curve. 
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3.4.4 Fibrinolytic activity of anti-platelet scFv/uPA-T in-vitro 
To see if anti-PLT scFv/uPA-T has any PA activity in its native form, we performed 
casein zymography. We confirmed that anti-PLT scFv/uPA-T is expressed as a zymogen 
with negligible plasminogen conversion activity (Figure 3-13 A), which drastically 
increased upon thrombin activation. This result appears to be similar though less potent 
than that seen with the non-fused thrombin activatable uPA-T, which served as our 
positive control. Purified anti-PLT scFv/uPA-T migrated as a predominant single band at 
the predicted molecular weight of ~59 kDa and this was confirmed by Western blot 
(Figure 3-13 B). Cleavage by thrombin generated two bands that under reducing 
conditions results in a protein fragments of ~30 kDa (Figure 3-13 B).  
To estimate the fibrinolytic activity of the anti-PLT scFv/uPA-T upon thrombin 
conversion into a two-chain form capable of activating plasminogen, fibrin plate analysis 
was performed, which revealed strong, dose dependent fibrinolytic activity of the anti-
PLT scFv/uPA-T, comparable with the non-fused uPA-T (Figure 3-13 C).  
 
3.4.5 Thrombolytic efficacy of anti-PLT scFv/uPA-T in mouse models 
of vascular thrombosis 
We tested whether anti-PLT scFv-uPA-T thromboprophylaxis could effectively prevent 
occlusive thrombi using the FeCl3 model of carotid arterial injury in mice as previously 
described (139). Equimolar amounts of anti-PLT scFv/uPA-T, un-bound uPA-T, or PBS 
were IV injected into anesthetized hαIIb+ mice prior to FeCl3 carotid artery injury (98). 
In preliminary data (Figure 3-14), it appears that administration of uPA-T or PBS does 
not prevent vascular occlusion after 5 min of infusion, while injection of anti-PLT 
scFv/uPA-T was protective even 10 hrs post infusion.  
We also used the cremaster arteriole injury model, which allows for in situ 
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visualization 
 
 
Figure 3-10. Characterization of the anti-PLT scFV/uPA-Ts. (A) and (B) SDS-
PAGE gels of eluted proteins stained with GelCode blue stain reagent, and (C) Western 
blot of the anti-PLT scFv/uPA-Ts using an HRP-moAb against the flag tag as the 
detecting antibody. 
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Figure 3-11. Flow cytometric analysis of haIIbb3 binding by anti-PLT 
scFv/uPA-T. (A) Human (A), (B) haIIb+ mouse and (C) WT mouse platelets were 
incubated with 0.1 mg/ml of 312.8 anti-PLT scFv/uPA-T (red), moAb 312.8 (red) or 
184.2 anti-PLT scFv/uPA-T (green), and moAb 184.2. Representative study of three 
separate flow cytometric analyses is shown. Mean fluorescence of 105 platelets was 
measured. 
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Figure 3-12. Binding of anti-PLT scFv/uPA-T to immobilized hαIIbβ3. (A) 
ELISA studies with both haIIbhβ3 in wells with the various concentrations of anti-PLT 
scFv/uPA-T, uPA-T, or a unrelated fusion protein, anti-GPA scFv/uPA-T indicated. (B) 
Binding of labeled anti-PLT scFv/uPA-T to immobilized hαIIbhβ3. Varying 
concentrations of labeled anti-PLT scFv/uPA-T were incubated with hαIIbhβ3 or BSA 
coated wells for 1 hr. N=3, done in duplicate each. Mean ± 1 SD of binding is shown.  
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Figure 3-13. Enzymatic activity of anti-PLT scFv/uPA-T. The intrinsic and 
thrombin-induced plasminogen activator activities of the anti-PLT scFv/uPA-T were 
analyzed using (A) casein zymography and (B) Western blot with a mouse anti lmw-
scuPA antibody (American Diagnostica) as primary antibody. (C) Fibrin plate analysis 
revealed a strong and dose dependent fibrinolytic activity of the anti-PLT scFv/uPA-T 
similar to uPA-T.  
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Figure 3-14. Prophylactic thrombolysis by anti-PLT scFV/uPA-T in a FeCl3 
carotid artery injury model. Indicated products were infused at time zero and then a 
FeCl3 injury followed by a 30-min measurement of carotid artery blood flow was 
monitored at the indicated time points. Mean ± 1 SD are shown. N = 3. 
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visualization of thrombus development in real time to test our fusion protein. In these 
studies, hαIIb+ male mice were IV infused with equimolar amounts of anti-PLT 
scFv/uPA-T, un-bound uPA-T or PBS 5 hrs before inducing injury. Mice infused with 
either PBS (Figure 3-15 A) or uPA-T (Figure 3-15 B) showed similar fibrin deposition 
with only a small difference in platelet accumulation. Mice infused with anti-PLT 
scFv/uPA-T fusion protein (Figure 3-15 C) showed a significant reduction in both fibrin 
deposition and platelet accumulation. These preliminary studies support our fusion 
protein as being both an effective and long-lasting thromboprophylactic agent. 
 
 
3.5 Discussion 
 
Thrombotic arterial occlusion is the proximate cause of myocardial infarction and stroke. 
Occlusive thrombi impair blood flow to vital organs causing local oxygen deprivation, 
tissue necrosis and organ dysfunction. Current PA therapy is not used for prophylaxis 
due to their rapid clearance, (<30 min) risk of bleeding and neurotoxic side effects. 
Newly designed mutant PAs with enhanced potency and fewer side effects may improve 
this outcome (140-145), but their selective diffusion into occlusive clots has not been 
tested and none has been designed for prophylactic use. An ideal thromboprophylactic 
agent needs to have a prolonged lifespan in the blood, circulate as a pro-drug, and target 
incipient thrombi while sparing hemostatic clots.  
Recent studies have targeted PAs to red bloods cells (RBC) by re-infusing ex-vivo 
modified cells (139) and by IV injection of PAs fused to either Fab’ or scFv from anti-RBC 
(126, 146). These studies showed that the fused proteins provided prolonged 
thromboprophylaxis against lethal stroke and pulmonary embolism with less re- 
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Figure 3-15. Platelet and fibrin accumulation in laser-induced arteriole 
injuries in treated haIIb+ mice. Analysis of in situ laser injury in cremaster 
arterioles 5 hrs post treatment with (A) PBS, (B) uPA-T, and (C) anti-PLT scFv-uPA-T. 
Average platelet accumulation (green) and fibrin clot accumulation (red) are shown over 
a 3-min window after a laser injury. N=2 mice per study with 10 injuries per mouse.  
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bleeding after tail amputation (125, 146) or intracerebral hemorrhage after traumatic 
brain injury (147). But RBCs are not specifically targeted to growing thrombi, especially 
arterial thrombi. Platelets, on the other hand, become incorporated into incipient clots, 
which makes them ideal for a thromboprophylaxis design. Our group has shown that 
uPA ectopically expressed in platelets using a transgenic approach is safe and effective in 
preventing arterial and venous thrombosis and that transfusion of 5% of the platelet 
mass protects wild type mice from clotting without causing systemic fibrinolysis or 
spontaneous bleeding aside from post-partum hemorrhage (84). 
We used a similar strategy as the RBC-PA studies, utilizing platelets to deliver the 
thrombin-activatable mutant uPA-T to newly formed clots. We hypothesize that this 
approach will; 1) increase the half-life of uPA-T in circulation, 2) significantly increase 
delivery of uPA-T to sites of incipient thrombus formation, 3) limit systemic side effects 
due to local activation of uPA-T by thrombin, and 4) bypass mature hemostatic clots not 
actively recruiting platelets with less thrombin present. 
We developed a recombinant fusion protein composed of a scFv from a moAb 
(Figure 3-1) against the hαIIb subunit of the platelet integrin receptor αIIbβ3 fused to 
thrombin-activatable uPA-T (Figure 3-2). The new zymogen, anti-PLT scFv/uPA-T, 
bound specifically to human platelets, with a Bmax of ~2x104 molecules per cell, assuming 
approximately 80,000 GPIIb/IIIa complexes on the surface of each platelet (90). Anti-
PLT scFv/uPA-T also bound to hαIIb+, but not WT, mouse platelets (Figures 3-11 and 3-
12). The fusion protein exhibited pronounced activity, but only upon thrombin activation 
and conversion of uPA-T into its active form (Figure 3-13). To test thromboprophylaxis, 
we used two mouse models of acute thrombotic occlusion in response to vascular injury. 
In the FeCl3 carotid artery injury model, it appears that uPA-T or PBS does not prevent 
vascular occlusion 5 min after administration, while anti-PLT scFv/uPA-T was protective 
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even after 10 hrs post infusion (Figure 3-14). When analyzing hαIIb+ mice with the 
cremaster arteriole injury model 5 hrs after administering the anti-PLT scFv/uPA-T, we 
saw a significant reduction in both fibrin deposition and platelet accumulation compared 
to mice that had been treated with uPA-T or PBS (Figure 3-15). 
These preliminary results from the mouse models of vascular injury concur with 
our expectation that the anti-PLT scFv/uPA-T binds rapidly to the surface of platelets in 
hαIIb+ mice, while uPA-T is rapidly eliminated from circulation through hepatic 
clearance. Further studies should provide us with a better picture as it relates to platelet 
survival, biodistribution of the protein in the lungs, liver or spleen, and the duration of 
fibrinolytic activity. It also remains to be determined whether the platelet-bound fusion 
protein induces bleeding or, conceivably, re-bleeding, at doses that prevent clot buildup. 
We propose a potentially clinically feasible means to target a pro-drug using the 
natural procoagulant platelet-thrombin pathway to induce fibrinolysis and reduce the 
need for higher dosage. If effective, the design of the fusion protein and targeting 
strategy allows for adaptation to other pro-drugs with diverse activities (anti-
inflammatory, anti-oxidant) that can be targeted to platelets or other cell types, (e.g., 
neutrophils, monocytes) that target to sites of injury in other disorders. 
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Chapter 4 
 
 
Summary, and future directions 
 
PAs assist in maintaining blood fluidity by activating plasmin to degrade fibrin clots (62, 
148, 149), but they have limited clinical utility due to their rapid clearance and 
problematic side effects, especially untoward bleeding. Their clinical limitations make 
PAs unsuitable for prophylactic therapy, which merit the need for newer drugs that are 
safer and better suited for effective fibrinolysis. In theory, a more ideal 
thromboprophylactic agent should have the following properties: 1) has a prolonged 
lifespan in the blood, 2) circulates as a prodrug, 3) targets incipient thrombi, while 
sparing hemostatic clots, and 4) remains amenable to regulation. Platelets provide the 
first line of defense in the process of hemostasis, by localizing and sustaining the blood 
loss and adhering to the site of injury. Their natural targeting function makes them an 
ideal candidate for therapeutic delivery of bioactive agents. We concentrated on two 
distinct strategies that in proof of principle studies are promising for effective and 
targeted platelet directed thrombolytic therapy.  
 In our first approach, we were interested in target delivery of uPA to the injured 
site by expressing the protein at high levels in developing megakaryocytes so that it is 
stored in platelet alpha granules and released upon activation. These findings were 
previously demonstrated in our laboratory with transgenic mice that ectopically express 
uPA within platelets (84). The uPA-loaded platelets showed that they could selectively 
lyse emboli without inducing bleeding, systemic decrease in fibrinogen levels or increase  
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in D-dimers. Expression of uPA within platelets also is the underlying mechanism in 
Quebec platelet disorder, wherein patients have mild bleeding (105); supporting the 
contention that platelets laden with uPA may be an effective PA with little systemic 
bleeding. These patients show significant post-traumatic bleeding, but this is 
controllable with tranexamic acid (150-153), suggesting a therapeutic strategy to treat 
untoward bleeding from uPA-ladened platelets as a PA strategy. 
We were interested in translating these findings into clinical use beginning with 
ex-vivo generated megakaryocytes and platelets for thrombolytic targeted therapy. No 
one had successfully produced sufficient ex-vivo generated platelets before and it is 
possible that given the plastic surfaces and slow release of ex vivo generated platelets 
from megakaryocytes that we would have difficulty generating large numbers of non-
activated platelets. Because of older literature suggesting that circulating 
megakaryocytes might become lodged in the lungs and release platelets thereafter (35, 
36, 39), we tested whether infusing ex-vivo generated megakaryocytes directly would 
lead to released platelets within the lungs. We found that we can achieve a significant 
number of donor-derived platelets from these infused megakaryocytes in a murine 
model with a delay of 3-90 minutes. While these platelets had a slightly shortened half-
life compared to donor-derived platelets, they had many features of normal platelets and 
were functional in two in vivo assays. In a radiation-induced thrombocytopenia model, 
we showed that these platelets can boost the platelet count as well as donor-derived 
platelets and in this system, may even last better. Whether these megakaryocyte-derived 
platelets enhanced post-radiation survival has yet to be tested. In the FeCl3 carotid artery 
model, we not only tested platelet efficacy, but showed that megakaryocytes derived from 
transgenic mice with platelet-uPA expression, when infused into the recipient mouse 
completely prevented thrombus development. We take this as the first step in a proof-of-
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principle that our approach of infusing modified megakaryocytes may be a model for the 
targeted delivery of a PAs to a site of untoward thrombosis and may be useful for 
targeted thromboprophylaxis.  
In our second approach, we extended a strategy developed by our colleagues of 
endothelial and RBCs targeting fused to a thrombin activated pro-enzyme uPA-T (85, 
126) to platelets. They had shown targeted efficient and safe thromboprophylaxis in 
several clinically relevant models including after pulmonary injury. We extended their 
strategy by using a platelet-delivery system with uPA-T that is activated and released 
from the antibody by thrombin generated at the site of active clotting. Since platelets 
target new thrombi better than RBCs, we believe that there may be advantages for the 
binding of uPA-T to the platelet surface over the red cell surface. Our fusion uPA-T that 
had an scFv derived from an anti-haIIb moAb generously provided by my colleagues Drs. 
Richard Aster and Daniel Bougie at the Blood Center in Wisconsin, bound specifically to 
human platelets through its αIIbb3 receptor. This fusion uPA-T also bound to transgenic 
mice that had chimeric haIIbmb3 are their platelets, but not to WT platelets. The fusion 
protein exhibited pronounced activity, but only upon thrombin activation and 
conversion of uPA-T into its active form. In preliminary thromboprophylactic 
experiments using a mouse model of vascular injury, it appears that the fusion protein 
was long-lasting and prevented thrombus development for at least 10 hrs post-infusion 
in the FeCl3 carotid artery injury model without obvious bleeding complications, while 
uPA-T or PBS did not prevent vascular occlusion 5 min after administration. In 
analyzing hαIIb+ mice with the cremaster arteriole injury model 5 hrs after administering 
of the fusion protein, we also saw a significant reduction in both fibrin deposition and 
platelet accumulation compared to mice that had been treated with uPA-T or PBS. These 
data are preliminary, and need to be repeated.  
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 For the future, the studies presented here serve as proof-of-principle of two novel 
therapeutic approaches for the delivery of uPA especially for thromboprophylaxis. Both 
strategies include using platelets to target uPA to incipient thrombi and hopefully to 
avoid more mature thrombi and enhance efficacy and selectivity of the PA. For the 
megakaryocyte-derived platelet strategy our ultimate goal would be to establish a self-
replicating human cell line that upon appropriate stimulus terminally differentiates into 
megakaryocytes expressing uPA. Upon infusion of these cells, we anticipate efficacious 
release of platelets from these cells. For our second approach involving anti-PLT 
scFv/uPA-T, safety and pharmacokinetics and pharmacodynamic studies need to be 
completed in mice. A Phase I safety trial would be needed in a setting associated with a 
high risk of thrombosis that may benefit from thromboprophylaxis. This may be patients 
undergoing stent placement or a subgroup of such patients that are at higher risk of such 
thrombi, like in patients with multivessel coronary artery disease with a higher 
prevalence of coronary risk factors when compared to patients without (154).  
If either approach proves to be clinically useful, the strategies developed here for 
platelet-targeted therapy may be extended to other systems such as the delivery of agents 
that are anti-inflammatory, like thrombomodulin either stored within platelets or a 
recombinant thrombomodulin protein designed by our colleague, Bi-Sen Ding (155) at 
the University of Pennsylvania with a thrombin cleavage site, transforming thrombin 
into an anti-inflammatory molecule. Our approach can also be adapted to produce anti-
angiogenic agents by designing platelets stored with negative angiogenic regulators such 
as thrombospondin-1, endostatin, and angiostatin to inhibit tumor progression. We can 
also target the tumor with scFvs with a cleavage site for cathepsin-B, which is over 
expressed in many tumor cells and tumor endothelial cells. The modular design used in 
our scFv can be applied to other cells that can be targeted and are essential in treating 
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other malignancies such as infectious disease. For example neutrophils and monocytes 
can be targeted via the myeloid FcαRI (CD89) receptor which has been identified as an 
effective target molecule (156), and is expressed exclusively in myeloid cells. 
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